var title_f22_63_23536="HSG showing submucous fibroids";
var content_f22_63_23536=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F80816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F80816&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Hysterosalpingogram showing multiple filling defects due to submucous myomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baramki, TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright &copy; 2005 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23536=[""].join("\n");
var outline_f22_63_23536=null;
var title_f22_63_23537="Prenatal ultrasound image of multivessel umbilical cord";
var content_f22_63_23537=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65418&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Prenatal ultrasound image of multivessel umbilical cord",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 285px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multivessel cord.",
"    <br>",
"     (Panel A) Several umbilical vessels are identified in the single umbilical cord from thoracopagus conjoined twins.",
"     <br>",
"      (Panel B) A potential pitfall for multivessel cord in a case of an umbilical cord knot.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23537=[""].join("\n");
var outline_f22_63_23537=null;
var title_f22_63_23538="Apical pneumothorax";
var content_f22_63_23538=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest x-ray with apical pneumothorax",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 420px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The film demonstrates a small left apical spontaneous pneumothorax. The visceral pleural line is marked by the red arrows.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23538=[""].join("\n");
var outline_f22_63_23538=null;
var title_f22_63_23539="Technetium Tc-99m medronate: Patient drug information";
var content_f22_63_23539=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Technetium Tc-99m medronate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/7/22642?source=see_link\">",
"     see \"Technetium Tc-99m medronate: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7734546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      CIS-MDP&trade;;",
"     </li>",
"     <li>",
"      DRAXIMAGE&reg; MDP-25;",
"     </li>",
"     <li>",
"      MDP Multidose",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13374325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560724",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with an imaging test of the bones.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13374324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560536",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to technetium Tc 99m medronate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13374328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low calcium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13374329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13374330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13374327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13374331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13374332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17065 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23539=[""].join("\n");
var outline_f22_63_23539=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7734546\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374325\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374324\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374328\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374329\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374330\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374327\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374331\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13374332\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/7/22642?source=related_link\">",
"      Technetium Tc-99m medronate: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_63_23540="Paraaortic node dissection5";
var content_f22_63_23540=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F65768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F65768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Full exposure of left paraaortic node space",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 370px; height: 277px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ken Hatch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23540=[""].join("\n");
var outline_f22_63_23540=null;
var title_f22_63_23541="Examination of finger DIP joint extension";
var content_f22_63_23541=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58818%7EEM%2F73661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58818%7EEM%2F73661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examination of finger DIP joint extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 309px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distal interphalangeal (DIP) joint extension should be evaluated independently of other finger movements, as depicted in the photograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examination of finger DIP joint flexion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flexion of the distal interphalangeal (DIP) joint is evaluated independently of other finger movements.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rebecca Bassett, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23541=[""].join("\n");
var outline_f22_63_23541=null;
var title_f22_63_23542="Clinical use of echinacea";
var content_f22_63_23542=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical use of echinacea",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/63/23542/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/63/23542/contributors\">",
"     Robert B Saper, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/63/23542/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/63/23542/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/63/23542/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/63/23542/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/63/23542/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinacea species are commonly referred to as coneflowers, a group of native American wildflowers from the daisy family",
"    <span class=\"nowrap\">",
"     (Asteraceae/Compositae)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef71115 \" href=\"UTD.htm?38/0/38915\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/1\">",
"     1",
"    </a>",
"    ]. Echinacea is indigenous to North America and was used by Native Americans in the Great Plains. Samples of echinacea have been found in archeological digs from the 1600s, thought to be the location of Lakota Sioux Indian village sites [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/2\">",
"     2",
"    </a>",
"    ]. Native Americans were noted to use echinacea both topically and systemically for ailments such as burns, snakebites, pain, cough, and sore throat [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Various echinacea species including Echinacea purpurea, E. angustifolia, and E. pallida have been touted as \"immune stimulants\" by a number of investigators [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/4\">",
"     4",
"    </a>",
"    ]. Medicinal preparations of root and above-ground parts of echinacea species have been the subject of in vitro, animal, and human studies to evaluate their possible mechanism(s), safety, and efficacy.",
"   </p>",
"   <p>",
"    At present, echinacea is mainly used for treating and preventing uncomplicated upper respiratory tract infections such as the common cold [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/5\">",
"     5",
"    </a>",
"    ]. Sales of echinacea in the United States in 2008 were estimated to be $15.1 million, a 4.5 percent increase from 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/6\">",
"     6",
"    </a>",
"    ]. The National Health Interview Survey found that echinacea was the third most common natural product used by adults in the US in 2007, used by 4.8 million adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/7\">",
"     7",
"    </a>",
"    ]. Echinacea was the most commonly used herbal product by children in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/7\">",
"     7",
"    </a>",
"    ]. In Germany, more than 2 million physicians' prescriptions for echinacea are filled each year [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30537?source=see_link\">",
"     \"The common cold in adults: Treatment and prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinacea products contain a variety of bioactive ingredients including echinacosides, caffeic acids, alkylamides, polysaccharides, and glycoproteins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/8\">",
"     8",
"    </a>",
"    ]. Though several echinacea products are standardized to the amount of echinacosides, there is no general consensus on the active component(s) of echinacea responsible for its purported medicinal properties.",
"   </p>",
"   <p>",
"    In vitro, echinacea causes macrophage activation and the release of tumor necrosis factor, interleukin 1, interleukin 6, and interferon [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. Echinacea has been noted to have antiviral activity against influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/12\">",
"     12",
"    </a>",
"    ], herpes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/13\">",
"     13",
"    </a>",
"    ], and poliovirus. Phenolic compounds present in echinacea demonstrate antioxidant activity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/14\">",
"     14",
"    </a>",
"    ]. It has also been reported to have antiinflammatory activity through inhibition of lipoxygenase and cyclooxygenase [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/15\">",
"     15",
"    </a>",
"    ] and is able to stimulate the anterior pituitary-adrenal cortex.",
"   </p>",
"   <p>",
"    In animal studies, echinacea affects several aspects of the immune system, in part by increasing the number of circulating white blood cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/16\">",
"     16",
"    </a>",
"    ]. Echinacea also increases phagocytosis, promotes activity of lymphocytes, stimulates cytokine production, triggers the alternate complement pathway, and modulates apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL TRIALS/INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many clinical studies have attempted to elucidate the safety and effectiveness of echinacea. Unfortunately, many of these studies have poor methodology and are difficult to interpret conclusively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/19\">",
"     19",
"    </a>",
"    ]. However, several randomized, double-blind, placebo-controlled trials have been undertaken and are of sufficient quality to derive useful information, particularly around the use of echinacea for upper respiratory tract infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Upper respiratory tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinacea is commonly used for the treatment and prevention of nonspecific upper respiratory tract infections (URI).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echinacea research is challenging because there are differing opinions regarding the best echinacea species, plant part, active component(s), and dose. Echinacea products used in studies are often not standardized. Several controlled trials of echinacea for URI prior to 2000 showed a decrease in symptom intensity and duration. Criticisms of these include that the studies varied greatly in their methodological quality and the type of echinacea used [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Since then, several well-designed studies have found that echinacea is no better than placebo for the treatment of URI [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/21-26\">",
"     21-26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two randomized trials compared a combined pill of Echinacea purpurea and angustifolia versus placebo in participants who had cold symptoms for less than 36 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/21,22\">",
"       21,22",
"      </a>",
"      ]. There was no significant difference in the mean duration or severity of cold symptoms. No treatment effect could be demonstrated after controlling for a number of variables, including symptom duration prior to enrollment.",
"     </li>",
"     <li>",
"      A randomized trial in 407 children ages 2 to 11 with 707 URI episodes treated patients at the onset of URI symptoms with either dried pressed Echinacea purpurea juice of the above-ground herb harvested at flowering or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/23\">",
"       23",
"      </a>",
"      ]. Treatment was continued until resolution of the URI or a maximum of 10 days. Compared with placebo, echinacea did not reduce duration of symptoms (9 versus 9 days), days of fever (0.81 versus 0.64 days), number of days of peak severity (1.60 versus 1.64 days), severity of URI symptoms, peak severity of symptoms, or parental assessment of severity. Overall, adverse events were similar in the two groups, but a significantly higher percentage of patients treated with echinacea developed a rash (7.1 versus 2.7 percent).",
"     </li>",
"     <li>",
"      A randomized trial compared three times daily treatment with Echinacea purpurea 100 mg (freeze-dried pressed juice from the aerial portion of the plant) or placebo in 128 adults [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/24\">",
"       24",
"      </a>",
"      ]. Treatment was started within 24 hours of the onset of cold symptoms and continued until resolution of symptoms or for a maximum of 14 days. There were no significant differences in symptom scores or in time to resolution of symptoms.",
"     </li>",
"     <li>",
"      A randomized trial examined the effects of three different preparations of Echinacea angustifolia root (extracted with supercritical carbon dioxide, 60 percent ethanol, or 20 percent ethanol) and placebo in 399 volunteers who were challenged with rhinovirus [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/25\">",
"       25",
"      </a>",
"      ]. Treatment was administered as a 1.5 mL tincture three times daily (approximately equivalent to a daily dose of 900 mg of echinacea root). None of the preparations had an effect significantly different from placebo on mean total symptom score or on the measured weight of nasal secretions. Whether other formulations or dosages of echinacea are effective is unknown. Critics of the study argue that the dosage was inadequate and that the aerial parts of Echinacea purpurea are more active [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Well-designed studies of echinacea have not generally found it to be efficacious for the prevention of community-acquired URI [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/5,27\">",
"     5,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized, controlled trial of 109 patients with a history of more than three colds or respiratory infections in the preceding year, randomly assigned the study subjects to receive 4 mL fluid extract of Echinacea purpurea or 4 mL of placebo juice twice daily [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/27\">",
"       27",
"      </a>",
"      ]. The incidence and severity of colds and respiratory infections were determined during eight weeks of follow-up, based upon patient reported symptoms together with findings on physical examination. During the eight-week treatment period, 35 of 54 patients (65 percent) in the echinacea group and 40 of 54 patients (74 percent) in the placebo group had at least one cold or respiratory infection (relative risk 0.88, 95% CI 0.60-1.22). The average number of colds and respiratory infections per patient was 0.78 in the echinacea group and 0.93 in the placebo group (difference 0.15, CI -0.12-0.41). The median duration of colds and respiratory infections was 4.5 days in the echinacea group and 6.5 days in the placebo group (difference 2 days, CI -1-+3 days). There were no significant differences between treatment groups in the number of infections in each category of severity. Side effects were observed in 11 patients (20 percent) of the echinacea group and in 7 patients (13 percent) of the placebo group (p = 0.44).",
"     </li>",
"     <li>",
"      A randomized trial assigned 302 adults to receive E. purpurea, E. angustifolia, or placebo for 12 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/5\">",
"       5",
"      </a>",
"      ]. The time until onset of the first URI was not significantly different for the three groups (66, 69, and 65 days, respectively). There were also no significant differences in URI rates for the two echinacea groups compared to placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Experimental studies have also generally not found that echinacea is effective in preventing URI after challenge with rhinovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/5,25,28,29\">",
"     5,25,28,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small trial randomly assigned 48 adults to receive echinacea (2.5 mL three times daily) or placebo for seven days before and seven days after nasal inoculation with rhinovirus type 39 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/29\">",
"       29",
"      </a>",
"      ]. There was a similar rate of microbiological infection with rhinovirus in both groups (92 versus 95 percent). There was a trend toward fewer patients treated with echinacea developing clinical colds (58 versus 82 percent, p = 0.11) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial examined the effects of three different preparations of Echinacea angustifolia root (extracted with supercritical carbon dioxide, 60 percent ethanol, or 20 percent ethanol) and placebo in 399 volunteers who were challenged with rhinovirus [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/25\">",
"       25",
"      </a>",
"      ]. Treatment was administered three times daily with a 1.5 mL tincture (the active preparation contained the equivalent of 300 mg of echinacea root) for five days prior to rhinovirus challenge. Rates of infection and clinical URI were not significantly different for any of the preparations or placebo.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SAFETY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although echinacea is usually well tolerated, side effects can occasionally occur. These include dyspepsia, diarrhea, and unpleasant taste. Fever along with nausea and vomiting have also been reported.",
"   </p>",
"   <p>",
"    Allergic reactions can occur in individuals sensitive to the",
"    <span class=\"nowrap\">",
"     Asteraceae/Compositae",
"    </span>",
"    family. Patients allergic to ragweed, chrysanthemums, marigolds, and daisies may have reactions to echinacea [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/30\">",
"     30",
"    </a>",
"    ]. One trial found that rash was also more frequent in children treated with oral echinacea compared with placebo (7.1 versus 2.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One case report of anaphylaxis associated with use of Echinacea angustifolia and Echinacea purpurea has been published; however, the exact mechanism and amount of concern remain controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Use in autoimmune disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immune stimulating effects of echinacea have led to concerns regarding the use of echinacea in patients with autoimmune disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Despite these concerns, little is known regarding the exacerbation of autoimmune illnesses due to echinacea. Two cases of pemphigus vulgaris exacerbations possibly related to echinacea use have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/34\">",
"     34",
"    </a>",
"    ]. One case of renal tubular acidosis due to Sjogren's syndrome has been associated with echinacea use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/35\">",
"     35",
"    </a>",
"    ]. In contrast, a pilot study in patients with low-grade autoimmune idiopathic uveitis found that treatment with Echinacea purpurea extract was associated with shorter treatment periods with steroids needed to induce remission [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Use in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cohort study followed pregnant women who contacted the Toronto Motherisk Program about gestational use of echinacea [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/37\">",
"     37",
"    </a>",
"    ]. There were 206 women who used echinacea products in pregnancy (112 in the first trimester). No increased risk for still births, spontaneous abortions, and major malformations occurred for the women who used echinacea compared to 206 controls matched for age, alcohol use, and cigarette smoking. A systematic review also did not find evidence suggesting that Echinacea is teratogenic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/38\">",
"     38",
"    </a>",
"    ]. Nonetheless, until more studies are done, it is prudent to avoid echinacea during pregnancy and lactation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HERB-DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of its immunostimulating activity, echinacea may interfere with immunosuppressant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/30\">",
"     30",
"    </a>",
"    ]. One study in healthy volunteers found that echinacea can impact CYP3A and CYP1A2 activities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/39\">",
"     39",
"    </a>",
"    ]. Although there are no case reports of adverse interactions, caution should be used when administering echinacea along with drugs dependent on these enzymes for elimination.",
"   </p>",
"   <p>",
"    One in vitro study found that Echinacea can stimulate proliferation of cervical and breast cancer cells in the face of exposure to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/40\">",
"     40",
"    </a>",
"    ]. A potentially harmful interaction between Echinacea and doxorubicin is thus theoretically possible and requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is substantial product variation in species of echinacea, part of plant, formulation, and extraction method and thus dosages are not standardized. Typical dosages recommended by manufacturers and herbal experts and used in studies are 300 to 400 mg of dried extract three times daily, one cup of tea (1 gram root in 150 mL boiling water for 5 to 10 minutes) three times daily, and 0.25 to 1 mL of liquid alcohol extract three times daily [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/30\">",
"     30",
"    </a>",
"    ]. Many experts also believe that use more than eight weeks continuously is not advisable [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/41\">",
"     41",
"    </a>",
"    ], although several studies have revealed no significant adverse effects with up to 12 weeks of continuous use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     BRAND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different preparations of echinacea are available. New Good Manufacturing Practices for the dietary supplement industry have been established by the US FDA and were phased in from 2008 to 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23542/abstract/42\">",
"     42",
"    </a>",
"    ]. Until the effectiveness of these regulations have been confirmed, patients who choose to use echinacea can use products that have passed specified quality criteria by independent commercial laboratories (",
"    <a class=\"graphic graphic_table graphicRef61981 \" href=\"UTD.htm?34/27/35259\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44210?source=see_link\">",
"       \"Patient information: The common cold in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although echinacea may have some immune stimulating effects, the evidence to date does not support its efficacy in treating or preventing the common cold and we recommend not using it for these purposes (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echinacea appears to be relatively safe, although gastrointestinal side effects and allergic reactions have been reported. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As with other herbal preparations, variability of echinacea preparations is an obstacle to its potential use by patients and prescription by clinicians. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Brand'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link\">",
"       \"Overview of herbal medicine and dietary supplements\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/1\">",
"      Hobbs C. Enchinacea: A Literature Review. Herbal Gram 1994; 30:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/2\">",
"      Wedel W. Bur Am Ethn Bull 1936; 112:59.",
"     </a>",
"    </li>",
"    <li>",
"     Bauer R, Wagner H. Echinacea: Handbuch Fur Arzte, Apotheker und andere Naturwissencraftler, Wissenschaftliche Vorlagsgesellschaft, Stuttgart 1990.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/4\">",
"      Barrett B, Kiefer D, Rabago D. Assessing the risks and benefits of herbal medicine: an overview of scientific evidence. Altern Ther Health Med 1999; 5:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/5\">",
"      Melchart D, Walther E, Linde K, et al. Echinacea root extracts for the prevention of upper respiratory tract infections: a double-blind, placebo-controlled randomized trial. Arch Fam Med 1998; 7:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/6\">",
"      American Botanical Council. Herbal Supplement Sales Experience Slight Increase in 2008. Herbal Gram 2009; 82:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/7\">",
"      Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. Natl Health Stat Report 2008; :1.",
"     </a>",
"    </li>",
"    <li>",
"     Bauer R, Wagner H. Echinacea species as potential immunostimulatory drugs. In: Economic and Medicinal Plant Research, Wagner H (Ed), Academic Press, London 1991. p.253.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/9\">",
"      Braunig B, Dorn M, Limburg E, Knick E. Enhancement of resistance in common cold by Echinacea purpurea. Z Phytother 1992; 13:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/10\">",
"      Hwang SA, Dasgupta A, Actor JK. Cytokine production by non-adherent mouse splenocyte cultures to Echinacea extracts. Clin Chim Acta 2004; 343:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/11\">",
"      Sullivan AM, Laba JG, Moore JA, Lee TD. Echinacea-induced macrophage activation. Immunopharmacol Immunotoxicol 2008; 30:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/12\">",
"      Pleschka S, Stein M, Schoop R, Hudson JB. Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV). Virol J 2009; 6:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/13\">",
"      Sharma M, Anderson SA, Schoop R, Hudson JB. Induction of multiple pro-inflammatory cytokines by respiratory viruses and reversal by standardized Echinacea, a potent antiviral herbal extract. Antiviral Res 2009; 83:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/14\">",
"      Pellati F, Benvenuti S, Magro L, et al. Analysis of phenolic compounds and radical scavenging activity of Echinacea spp. J Pharm Biomed Anal 2004; 35:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/15\">",
"      M&uuml;ller-Jakic B, Breu W, Pr&ouml;bstle A, et al. In vitro inhibition of cyclooxygenase and 5-lipoxygenase by alkamides from Echinacea and Achillea species. Planta Med 1994; 60:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/16\">",
"      O'Hara M, Kiefer D, Farrell K, Kemper K. A review of 12 commonly used medicinal herbs. Arch Fam Med 1998; 7:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/17\">",
"      Luettig B, Steinm&uuml;ller C, Gifford GE, et al. Macrophage activation by the polysaccharide arabinogalactan isolated from plant cell cultures of Echinacea purpurea. J Natl Cancer Inst 1989; 81:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/18\">",
"      Di Carlo G, Nuzzo I, Capasso R, et al. Modulation of apoptosis in mice treated with Echinacea and St. John's wort. Pharmacol Res 2003; 48:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/19\">",
"      Melchart D, Linde K, Worku F, et al. Immunomodulation with echinacea - a systematic review of controlled clinical trials. Phytomedicine 1994; 1:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/20\">",
"      Melchart D, Linde K, Fischer P, Kaesmayr J. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev 2000; :CD000530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/21\">",
"      Barrett BP, Brown RL, Locken K, et al. Treatment of the common cold with unrefined echinacea. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/22\">",
"      Barrett B, Brown R, Rakel D, et al. Echinacea for treating the common cold: a randomized trial. Ann Intern Med 2010; 153:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/23\">",
"      Taylor JA, Weber W, Standish L, et al. Efficacy and safety of echinacea in treating upper respiratory tract infections in children: a randomized controlled trial. JAMA 2003; 290:2824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/24\">",
"      Yale SH, Liu K. Echinacea purpurea therapy for the treatment of the common cold: a randomized, double-blind, placebo-controlled clinical trial. Arch Intern Med 2004; 164:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/25\">",
"      Turner RB, Bauer R, Woelkart K, et al. An evaluation of Echinacea angustifolia in experimental rhinovirus infections. N Engl J Med 2005; 353:341.",
"     </a>",
"    </li>",
"    <li>",
"     www.herbalgram.org/default.asp?c=echinacea072605 (Accessed on April 17, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/27\">",
"      Grimm W, M&uuml;ller HH. A randomized controlled trial of the effect of fluid extract of Echinacea purpurea on the incidence and severity of colds and respiratory infections. Am J Med 1999; 106:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/28\">",
"      Turner RB, Riker DK, Gangemi JD. Ineffectiveness of echinacea for prevention of experimental rhinovirus colds. Antimicrob Agents Chemother 2000; 44:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/29\">",
"      Sperber SJ, Shah LP, Gilbert RD, et al. Echinacea purpurea for prevention of experimental rhinovirus colds. Clin Infect Dis 2004; 38:1367.",
"     </a>",
"    </li>",
"    <li>",
"     Echinacea. In: Natural Medicines Comprehensive Database, Prescriber's Letter Publisher, Stockton, CA 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/31\">",
"      Mullins RJ. Echinacea-associated anaphylaxis. Med J Aust 1998; 168:170.",
"     </a>",
"    </li>",
"    <li>",
"     The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines, 1st ed, Blumenthal M, et al (Eds), American Botanical Council, Boston 1998.",
"    </li>",
"    <li>",
"     Brinker F. Herb Contraindications and Drug Interactions, 2nd ed, Eclectic Medical Publications, Sandy, OR 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/34\">",
"      Soon SL, Crawford RI. Recurrent erythema nodosum associated with Echinacea herbal therapy. J Am Acad Dermatol 2001; 44:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/35\">",
"      Logan JL, Ahmed J. Critical hypokalemic renal tubular acidosis due to Sj&ouml;gren's syndrome: association with the purported immune stimulant echinacea. Clin Rheumatol 2003; 22:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/36\">",
"      Neri PG, Stagni E, Filippello M, et al. Oral Echinacea purpurea extract in low-grade, steroid-dependent, autoimmune idiopathic uveitis: a pilot study. J Ocul Pharmacol Ther 2006; 22:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/37\">",
"      Gallo M, Sarkar M, Au W, et al. Pregnancy outcome following gestational exposure to echinacea: a prospective controlled study. Arch Intern Med 2000; 160:3141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/38\">",
"      Perri D, Dugoua JJ, Mills E, Koren G. Safety and efficacy of echinacea (Echinacea angustafolia, e. purpurea and e. pallida) during pregnancy and lactation. Can J Clin Pharmacol 2006; 13:e262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/39\">",
"      Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004; 75:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23542/abstract/40\">",
"      Huntimer ED, Halaweish FT, Chase CC. Proliferative activity of Echinacea angustifolia root extracts on cancer cells: Interference with doxorubicin cytotoxicity. Chem Biodivers 2006; 3:695.",
"     </a>",
"    </li>",
"    <li>",
"     Newall CA, Anderson LA, Philpson JD. Herbal Medicine: A Guide for Healthcare Professional, The Pharmaceutical Press, London 1996.",
"    </li>",
"    <li>",
"     www.fda.gov/bbs/topcs/NEWS/2007/NEW01657.html (Accessed on October 09, 2007).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1389 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-189.41.172.26-6ADEC3818C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23542=[""].join("\n");
var outline_f22_63_23542=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL TRIALS/INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Upper respiratory tract infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SAFETY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Use in autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Use in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HERB-DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DOSE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      BRAND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/1389\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/1389|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?38/0/38915\" title=\"picture 1\">",
"      Echinacea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/1389|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/27/35259\" title=\"table 1\">",
"      Echinacea quality criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44210?source=related_link\">",
"      Patient information: The common cold in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/52/30537?source=related_link\">",
"      The common cold in adults: Treatment and prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_63_23543="General principles of kidney transplantation in children";
var content_f22_63_23543=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of kidney transplantation in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/63/23543/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/63/23543/contributors\">",
"     Ruth A McDonald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/63/23543/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/63/23543/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/63/23543/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/63/23543/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/63/23543/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5913719\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the estimated glomerular filtration rate (GFR) declines to less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    and the child is in stage 4 chronic kidney disease, it is time to start preparing the child and the family for renal replacement therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/1\">",
"     1",
"    </a>",
"    ]. Although there have been many advances in conservative renal replacement therapy, renal transplantation is the best treatment for children with end-stage kidney disease (ESKD). This was shown in a study from Australia and New Zealand, in which the risk for death was more than four times higher with dialysis than with renal transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/2\">",
"     2",
"    </a>",
"    ]. Over the last several years, renal allograft and patient survival have increased due to improvements in the care of young patients and advances in immunosuppressive therapy, thereby resulting in reduced frequency and severity of acute rejection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12774?source=see_link&amp;anchor=H363124528#H363124528\">",
"     \"Overview on renal replacement therapy (RRT) for children with chronic kidney disease\", section on 'Choice of RRT'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38394?source=see_link\">",
"     \"Immunosuppression in renal transplantation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will provide an overview of aspects of renal transplantation that should be considered in children. Immunosuppression, complications, and outcome of renal transplantation in children are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38394?source=see_link\">",
"     \"Immunosuppression in renal transplantation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22154?source=see_link\">",
"     \"Complications of renal transplantation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40680?source=see_link\">",
"     \"Outcomes of renal transplantation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913726\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17416903\">",
"    <span class=\"h2\">",
"     End-stage kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated incidence of ESKD (chronic kidney disease [CKD] stage 5 defined as a GFR &lt;15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m",
"    <sup>",
"     2",
"    </sup>",
"    ) in children varies throughout the world. It has been reported to be as high as 14.8 cases per million children in the United States and as low as four cases per million children below the age of 19 in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The renal diseases responsible for CKD in children are different from those observed in adult patients. For example, diabetic nephropathy and hypertension are rare causes of CKD in children but common in adults, whereas congenital renal and urologic anomalies are the most common cause of CKD in children.",
"   </p>",
"   <p>",
"    The incidence and etiology of CKD are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17416982\">",
"    <span class=\"h2\">",
"     Renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, approximately 800 renal transplants are performed in children below 18 years of age annually, which has been a stable rate over the past decade [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, a revised policy (Share 35) that preferentially allocated allografts from deceased donors (DD) under the age of 35 years to pediatric patients who were listed before their 18",
"    <sup>",
"     th",
"    </sup>",
"    birthday went into effect in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/5\">",
"     5",
"    </a>",
"    ]. In comparing data prior to and after the initiation of Share 35, there was an increase in the percentage of transplants originating from deceased donors (DD) from 42 to 58 percent, which may have reflected an effect from this policy change [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/6\">",
"     6",
"    </a>",
"    ]. There also has been an overall decrease in the mean wait time from 360 days to 165 days from being put on the wait list to transplantation. In addition, the implementation of Share 35 has reduced the racial disparity in the time to and probability of receiving a DD renal transplant.",
"   </p>",
"   <p>",
"    An increase in the number of histocompatibility antigen (HLA)-mismatched allografts has also increased; however, the patient and allograft survival has not declined [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other countries have also implemented policy changes to prioritize allocation of allografts from deceased donors to pediatric recipients. As an example, such a policy has been in place in France since 1995.",
"   </p>",
"   <p>",
"    In the NAPRTCS registry, more male children (approximately 60 percent) receive kidney transplants than female, primarily due to the higher numbers of males with congenital anomalies of the kidney and urinary tract (CAKUT) that progress to ESKD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/8\">",
"     8",
"    </a>",
"    ]. The ethnicity of pediatric recipients was white, black, and Hispanic in 59, 17, and 17 percent of the recipients, respectively.",
"   </p>",
"   <p>",
"    Based on the NAPRTCS data, the following etiologies were noted in children undergoing renal transplant, which are similar to the causes of CKD seen in children registered with chronic renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CAKUT including obstructive uropathy and renal",
"      <span class=\"nowrap\">",
"       aplasia/hypoplasia/dysplasia:",
"      </span>",
"      40 percent (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link\">",
"       \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Hereditary renal diseases (eg, polycystic kidney disease, nephronophthisis, cystinosis, congenital nephrotic syndrome, oxalosis, hereditary nephritis, atypical hemolytic uremic syndrome, and Drash syndrome): 15 percent",
"     </li>",
"     <li>",
"      Focal segmental glomerulosclerosis (FSGS): 12 percent",
"     </li>",
"     <li>",
"      Other causes of glomerulonephritis (both primary and secondary causes): 13 percent",
"     </li>",
"     <li>",
"      Renal infarction: 1 percent",
"     </li>",
"     <li>",
"      Wilms tumor: 0.5 percent",
"     </li>",
"     <li>",
"      Other identified causes: 13 percent",
"     </li>",
"     <li>",
"      Unknown: 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is some ethnic variation in the prevalence of the underlying etiology of ESKD [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/8\">",
"     8",
"    </a>",
"    ]. Although CAKUT is the most common diagnosis in all ethnic groups, it is less frequently a cause of ESKD in black children compared with white and Hispanic children (23 versus 52 percent). In contrast, FSGS is a much more common cause of ESKD in the black population (23 versus 9 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17417151\">",
"    <span class=\"h1\">",
"     ADVANTAGES OF RENAL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient survival is superior among children with a kidney allograft compared with those who remain on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. In addition, young children (below six years of age) are more likely to have improved growth after transplantation compared with those undergoing either chronic hemodialysis or peritoneal dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/9\">",
"     9",
"    </a>",
"    ]. As a result, renal transplantation is the preferred renal replacement therapy for children with ESKD. The quality of life is much better after renal transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40680?source=see_link&amp;anchor=H12#H12\">",
"     \"Outcomes of renal transplantation in children\", section on 'Patient survival'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40680?source=see_link&amp;anchor=H13#H13\">",
"     \"Outcomes of renal transplantation in children\", section on 'Growth after renal transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17417513\">",
"    <span class=\"h1\">",
"     PREEMPTIVE TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children frequently undergo",
"    <strong>",
"     primary or preemptive",
"    </strong>",
"    transplantation, in which transplantation is the first mode of treatment for ESKD. Preemptive transplants occur more frequently in children than adults because of the parents&rsquo; and patients&rsquo; desire to avoid dialysis when a living donor is available [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/10\">",
"     10",
"    </a>",
"    ]. When performed, this procedure most commonly involves a living donor who is related to the recipient. Children can also be listed for a preemptive deceased donor transplant.",
"   </p>",
"   <p>",
"    In the NAPRTCS registry the rate of preemptive transplant in children is approximately 24 percent. The rate of preemptive transplantation differs significantly between recipients of living (34 percent) and deceased donor (13 percent) allografts; and across races with whites having the highest rates (31 percent), followed by Hispanics (16 percent) and blacks (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It remains unclear whether preemptive transplantation is associated with better long-term outcome compared with transplantation while undergoing dialysis.",
"   </p>",
"   <p>",
"    Improved allograft",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    patient survival with preemptive transplantation have been reported from the NAPRTCS registry and from a single tertiary center of primary renal transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In a retrospective study of nearly 40,000 primary renal transplants in both children and adults from the United States Renal Data System (USRDS), preemptive transplantation compared with transplantation while undergoing dialysis was associated with a reduced risk of both allograft failure and death for deceased donor transplants (relative risk [RR] 0.75, 95% CI 0.67-0.84, and 0.84, 95% CI 0.72-0.99), and for living donor transplants (RR 0.73, 95% CI 0.62-0.83 and 0.69, 95% CI 0.56-0.85) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/12\">",
"     12",
"    </a>",
"    ]. In this study, preemptive transplantation was associated with racial minorities, patients with less education, and those who relied on Medicare for primary payment.",
"   </p>",
"   <p>",
"    Other studies have found that allograft and patient survival and the incidence of rejection were similar in patients transplanted preemptively versus those transplanted while already undergoing dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The largest of these studies was a multicenter European study that included 1113 first renal transplants in children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/15\">",
"     15",
"    </a>",
"    ]. Preemptive transplantation was associated with a lower rate of rejections in the first three years following transplantation (48 versus 63 percent). There was no statistical difference in allograft survival at six-year follow-up, although there was a trend that favored preemptive transplantation (82 versus 69 percent).",
"   </p>",
"   <p>",
"    There are some circumstances in which preemptive transplants cannot be performed or are not recommended. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Need for pretransplant nephrectomies (ie, malignant renovascular hypertension, chronic pyelonephritis, or nephrotic syndrome with the associated complications due to hypercoagulability)",
"     </li>",
"     <li>",
"      ESKD from autoimmune disease with persistently high titers of autoantibody (ie, antiglomerular basement membrane disease)",
"     </li>",
"     <li>",
"      Ongoing active infections",
"     </li>",
"     <li>",
"      Underlying renal disease is still active and associated with rapidly progressive disease (ie, hemolytic uremic syndrome or crescentic glomerulonephritis)",
"     </li>",
"     <li>",
"      If the patient or their caregivers are not yet able to cope with the regimented care necessary for the transplant recipient as exhibited by nonadherence to their CKD care",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based on the currently available data, we recommend preemptive renal transplantation if none of the above contraindications are present and there is a readily available living donor. If there is not an available living donor, we place the child on the active deceased donor waitlist in the chance that they may receive a preemptive transplant before needing dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913733\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are contraindications to renal transplantation in children which include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uncontrolled extra-renal malignancies",
"     </li>",
"     <li>",
"      Systemic sepsis",
"     </li>",
"     <li>",
"      Severe irreversible multisystem organ system failure not correctable by organ transplant",
"     </li>",
"     <li>",
"      Severe cardiac or pulmonary dysfunction in a patient who is not a candidate for multiorgan transplantation",
"     </li>",
"     <li>",
"      Life-threatening disorder of extra-renal origin that is not correctable by organ transplant",
"     </li>",
"     <li>",
"      Elevated levels of circulating antiglomerular basement membrane antibodies (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7432?source=see_link\">",
"       \"Treatment of anti-GBM antibody (Goodpasture's) disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22531?source=see_link\">",
"       \"Anti-GBM antibody disease: Recurrence after transplantation\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Previously, ABO incompatibility and the presence of cytotoxic antilymphocyte antibodies against the donor were contraindications to transplantation; however, subsequent advances with specific protocols have permitted such transplantation in some centers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Human immunodeficiency virus (HIV) infection was traditionally considered an absolute contraindication for transplantation. However, improvements in the long-term prognosis of those with HIV infection have prompted many transplant programs to reevaluate their policies regarding the exclusion of patients with HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15321?source=see_link&amp;anchor=H6#H6\">",
"     \"Solid organ transplantation in HIV-infected individuals\", section on 'Renal transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Renal transplantation should be delayed for several months in those with ongoing active infections, or if the disease responsible for renal failure is active and associated with rapidly progressive disease (eg, hemolytic uremic syndrome or crescentic glomerulonephritis). Transplantation should only be performed when there has been successful treatment of these conditions so that they do not negatively affect the allograft. Patients with hepatitis B or C infection should not be excluded unless they have active liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=see_link\">",
"     \"Evaluation of the potential renal transplant recipient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913747\">",
"    <span class=\"h1\">",
"     DONOR CHOICE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of kidney transplantation with a living donor are superior to those with a deceased donor. The NAPRTCS data reveal that five year allograft survival is greater in living donor compared with deceased donor allografts (80 versus 66 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/8\">",
"     8",
"    </a>",
"    ]. A multivariate analysis of United Network of Organ Sharing (UNOS) data showed that even recipients of kidneys from older living donors have a significant long-term allograft survival advantage over those who received a kidney from a young deceased donor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40680?source=see_link&amp;anchor=H4#H4\">",
"     \"Outcomes of renal transplantation in children\", section on 'Donor source'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Advantages associated with living donor renal transplantation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of delayed allograft function is lower.",
"     </li>",
"     <li>",
"      Long-term allograft survival is higher.",
"     </li>",
"     <li>",
"      Dialysis can be avoided, or the period on dialysis can be shortened because the time of transplantation is decided in advance. This may limit dialysis-related complications, such as growth impairment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these advantages, the proportion of living donors varies greatly among countries and regions. Several factors that may explain these differences include the activity level of deceased donor transplant programs in the region or country, cultural variations, and the manner in which parents are solicited for donation.",
"   </p>",
"   <p>",
"    Living donors should be informed of potential risks. Possible postoperative complications include abscess and hematoma. The incidence of mortality is low for donors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30697?source=see_link\">",
"     \"Evaluation of the living kidney donor and risk of donor nephrectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the general desirability of living donor allografts, a deceased donor may be preferred in settings in which there is a high risk of recurrent disease leading to loss of the allograft, as with rapidly progressive focal glomerulosclerosis. Support for this exception is provided by the finding that long-term survival of living and deceased donor allografts is similar among children with focal glomerulosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/18\">",
"     18",
"    </a>",
"    ]. The loss of benefit was associated with recurrent disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913754\">",
"    <span class=\"h1\">",
"     PRETRANSPLANT EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to renal transplantation, the recipient should undergo the following evaluation and preparation to reduce complications, and increase allograft and patient survival.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Detection of anti-Human Leukocyte Antigen (HLA) antibodies to the donor",
"     </li>",
"     <li>",
"      Correction of any significant urinary tract abnormality",
"     </li>",
"     <li>",
"      Detecting and treating any infection prior to transplantation",
"     </li>",
"     <li>",
"      Completion of routine childhood immunization, including",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/5/12374?source=see_link\">",
"       varicella vaccine",
"      </a>",
"     </li>",
"     <li>",
"      Review whether nephrectomy would be beneficial long-term",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913762\">",
"    <span class=\"h2\">",
"     Detection and consequences of sensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of preformed HLA antibodies are likely to result in severe antibody mediated rejection and early allograft loss. Several different assays are available to determine the sensitivity (ie, presence of HLA antibodies) of a potential transplant recipient to donor HLA antigens. These assays typically test for the presence of HLA antibodies by testing the serum from the recipient to a panel of HLA antigens or lymphocytes from different donors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link&amp;anchor=H13#H13\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\", section on 'Determination of sensitization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The final test of sensitization when a specific donor has been identified is the cross match, which screens for preformed anti-HLA antibodies that would injure the kidney from that specific donor. In the crossmatch, the recipient serum is incubated with the donor's lymphocytes in the presence of complement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=see_link&amp;anchor=H14#H14\">",
"     \"HLA and ABO sensitization and desensitization in renal transplantation\", section on 'Crossmatch'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913769\">",
"    <span class=\"h2\">",
"     Urinary tract abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lower urinary tract should be evaluated using a voiding cystourethrogram to detect any abnormality that should be corrected prior to transplantation in patients with history of congenital abnormalities of the urinary tract or infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Bladder and urethra abnormalities may be responsible for ureterohydronephrosis of the allograft, thereby increasing the risk of allograft loss. These and other abnormalities may increase the risk of urinary tract infection, and possibly urosepsis.",
"   </p>",
"   <p>",
"    Patients with high grade vesicoureteric reflux or permanent urinary infection should undergo nephroureterectomy to avoid the development of urosepsis. Children with lower tract uropathies (posterior urethral valves, Prune-belly syndrome, and neurogenic bladder) and abnormalities of bladder function should be assessed carefully with urodynamic studies. It may be necessary to enlarge the bladder with an intestinal segment in patients with a small pathologic bladder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44407?source=see_link\">",
"     \"Prune-belly syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36502?source=see_link\">",
"     \"Management of posterior urethral valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913776\">",
"    <span class=\"h2\">",
"     Infectious disease issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steps to prevent infectious complications associated with renal transplantation are essential. The urinary tract, skin, teeth, and sinuses should be carefully examined for signs of infection or site of chronic infection.",
"   </p>",
"   <p>",
"    Routine childhood immunizations should be completed, if possible, prior to immunosuppression, particularly if attenuated live virus vaccines are used. Live vaccines, such as varicella and measles, should be administered at least two months prior to transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913783\">",
"    <span class=\"h2\">",
"     Native nephrectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for native nephrectomy is controversial. Loss of residual excretory capacity and erythropoietin production are potential complications of native nephrectomy should the transplant fail.",
"   </p>",
"   <p>",
"    However, in certain cases, native nephrectomy may be beneficial, although data are limited. These indications include intractable urinary tract infection, high grade vesicoureteral reflux, severe refractory hypertension, significant polyuria, or persistent nephrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23543/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Native nephrectomy also has been suggested for children with X-Y gonadal dysgenesis and renal failure (Drash syndrome), as the frequency of Wilms' tumor is high if the kidneys are left in place. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=see_link\">",
"     \"Congenital and infantile nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6968166\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Patrick Niaudet, who contributed to an earlier version of this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=see_link\">",
"       \"Patient information: Kidney transplant (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=see_link\">",
"       \"Patient information: Planning for a kidney transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5913790\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal transplantation is the treatment of choice for children with end-stage kidney disease (ESKD) because of its superior patient survival rate compared with chronic dialysis. In addition, it is associated with better growth and developmental outcomes. (See",
"    <a class=\"local\" href=\"#H17417151\">",
"     'Advantages of renal transplantation'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40680?source=see_link\">",
"     \"Outcomes of renal transplantation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common cause of ESKD in children who undergo transplantation is congenital malformations of the kidney and urinary tract (40 percent), followed by glomerular disorders (25 percent) and",
"      <span class=\"nowrap\">",
"       hereditary/genetic",
"      </span>",
"      renal diseases (15 percent), particularly focal glomerulosclerosis in black patients. (See",
"      <a class=\"local\" href=\"#H5913726\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although it remains uncertain whether preemptive renal transplantation is associated with better long-term outcome compared with transplantation while undergoing dialysis, children frequently undergo",
"      <strong>",
"       preemptive",
"      </strong>",
"      transplantation, in which transplantation is the first mode of treatment for ESKD. This procedure most commonly involves a living donor who is related to the recipient. It occurs more frequently in children than adults because of the parents&rsquo; and patients&rsquo; desire to avoid dialysis when a living donor is available.",
"      <br/>",
"      <br/>",
"      Our approach is to offer preemptive renal transplantation to suitable transplant candidates if there is a readily available living donor. If there is not an available living donor, we place the patient on the active deceased donor waitlist in the chance that they may receive a transplant before needing dialysis. (See",
"      <a class=\"local\" href=\"#H17417513\">",
"       'Preemptive transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are few contraindications for renal transplantation as the modality of choice for renal replacement therapy in children with ESKD. They include sepsis, uncontrolled extra-renal malignancies, irreversible multiorgan failure, severe cardiac and pulmonary dysfunction not corrected by organ transplant, underlying life-threatening disorder not corrected by renal transplant, elevated levels of antiglomerular basement membrane antibodies, and a recent history of nonadherence to medical care.",
"     </li>",
"     <li>",
"      Graft survival is superior with a living donor versus a deceased donor allograft. (See",
"      <a class=\"local\" href=\"#H5913747\">",
"       'Donor choice'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pretransplant evaluation and preparation are key components for a successful transplant in the pediatric recipient. (See",
"      <a class=\"local\" href=\"#H5913754\">",
"       'Pretransplant evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Detection of anti-HLA antibodies to the donor",
"     </li>",
"     <li>",
"      Correction of any significant urinary tract abnormality",
"     </li>",
"     <li>",
"      Detecting and treating any infection prior to transplantation",
"     </li>",
"     <li>",
"      Completion of routine childhood immunization",
"     </li>",
"     <li>",
"      Review whether nephrectomy would be beneficial long-term",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/1\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/2\">",
"      McDonald SP, Craig JC, Australian and New Zealand Paediatric Nephrology Association. Long-term survival of children with end-stage renal disease. N Engl J Med 2004; 350:2654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/3\">",
"      Warady BA, Chadha V. Chronic kidney disease in children: the global perspective. Pediatr Nephrol 2007; 22:1999.",
"     </a>",
"    </li>",
"    <li>",
"     Organ Procurement and Transplant Network; Data. Available from: file://optn.transplant.hrsa.gov/latestData/viewDataReports.asp (Accessed on May 27, 2011).",
"    </li>",
"    <li>",
"     Organ Procurement and Transplant Network: Policies. Available from: file://optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs/policy_7.pdf (Accessed on May 27, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/6\">",
"      Amaral S, Patzer RE, Kutner N, McClellan W. Racial disparities in access to pediatric kidney transplantation since share 35. J Am Soc Nephrol 2012; 23:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/7\">",
"      Abraham EC, Wilson AC, Goebel J. Current kidney allocation rules and their impact on a pediatric transplant center. Am J Transplant 2009; 9:404.",
"     </a>",
"    </li>",
"    <li>",
"     North American Pediatric Renal Transplant Cooperative Study (NAPRTCS): 2010 Annual report. Rockville, MD. Available from: file://www.naprtcs.org (Accessed on May 27, 2011).",
"    </li>",
"    <li>",
"     North American Pediatric Renal Trials and Collaborative Studies 2008 Annual report. https://web.emmes.com/study/ped/annlrept/Annual%20Report%20-2008.pdf (Accessed on June 09, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/10\">",
"      Neu AM. Special issues in pediatric kidney transplantation. Adv Chronic Kidney Dis 2006; 13:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/11\">",
"      Vats AN, Donaldson L, Fine RN, Chavers BM. Pretransplant dialysis status and outcome of renal transplantation in North American children: a NAPRTCS Study. North American Pediatric Renal Transplant Cooperative Study. Transplantation 2000; 69:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/12\">",
"      Kasiske BL, Snyder JJ, Matas AJ, et al. Preemptive kidney transplantation: the advantage and the advantaged. J Am Soc Nephrol 2002; 13:1358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/13\">",
"      Flom LS, Reisman EM, Donovan JM, et al. Favorable experience with pre-emptive renal transplantation in children. Pediatr Nephrol 1992; 6:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/14\">",
"      Nevins TE, Danielson G. Prior dialysis does not affect the outcome of pediatric renal transplantation. Pediatr Nephrol 1991; 5:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/15\">",
"      Cransberg K, Smits JM, Offner G, et al. Kidney transplantation without prior dialysis in children: the Eurotransplant experience. Am J Transplant 2006; 6:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/16\">",
"      Shishido S, Hasegawa A. Current status of ABO-incompatible kidney transplantation in children. Pediatr Transplant 2005; 9:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/17\">",
"      Dale-Shall AW, Smith JM, McBride MA, et al. The relationship of donor source and age on short- and long-term allograft survival in pediatric renal transplantation. Pediatr Transplant 2009; 13:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/18\">",
"      Baum MA, Stablein DM, Panzarino VM, et al. Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int 2001; 59:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/19\">",
"      Churchill BM, Jayanthi RV, McLorie GA, Khoury AE. Pediatric renal transplantation into the abnormal urinary tract. Pediatr Nephrol 1996; 10:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/20\">",
"      Krieger JN, Stubenbord WT, Vaughan ED Jr. Transplantation in children with end stage renal disease of urologic origin. J Urol 1980; 124:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/21\">",
"      Warshaw BL, Edelbrock HH, Ettenger RB, et al. Renal transplantation in children with obstructive uropathy. J Urol 1980; 123:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/22\">",
"      Knoll G, Cockfield S, Blydt-Hansen T, et al. Canadian Society of Transplantation consensus guidelines on eligibility for kidney transplantation. CMAJ 2005; 173:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23543/abstract/23\">",
"      Ghane Sharbaf F, Bitzan M, Szymanski KM, et al. Native nephrectomy prior to pediatric kidney transplantation: biological and clinical aspects. Pediatr Nephrol 2012; 27:1179.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6120 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23543=[""].join("\n");
var outline_f22_63_23543=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5913790\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5913719\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5913726\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17416903\">",
"      End-stage kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17416982\">",
"      Renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17417151\">",
"      ADVANTAGES OF RENAL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17417513\">",
"      PREEMPTIVE TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5913733\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5913747\">",
"      DONOR CHOICE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5913754\">",
"      PRETRANSPLANT EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913762\">",
"      Detection and consequences of sensitization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913769\">",
"      Urinary tract abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913776\">",
"      Infectious disease issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5913783\">",
"      Native nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6968166\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5913790\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/0/22531?source=related_link\">",
"      Anti-GBM antibody disease: Recurrence after transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22154?source=related_link\">",
"      Complications of renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/36/7753?source=related_link\">",
"      Congenital and infantile nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=related_link\">",
"      Epidemiology, etiology, and course of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30697?source=related_link\">",
"      Evaluation of the living kidney donor and risk of donor nephrectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/55/26490?source=related_link\">",
"      Evaluation of the potential renal transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34570?source=related_link\">",
"      HLA and ABO sensitization and desensitization in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38394?source=related_link\">",
"      Immunosuppression in renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/41/36502?source=related_link\">",
"      Management of posterior urethral valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/46/40680?source=related_link\">",
"      Outcomes of renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12774?source=related_link\">",
"      Overview on renal replacement therapy (RRT) for children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/46/25315?source=related_link\">",
"      Patient information: Kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/15/12531?source=related_link\">",
"      Patient information: Planning for a kidney transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44407?source=related_link\">",
"      Prune-belly syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/61/15321?source=related_link\">",
"      Solid organ transplantation in HIV-infected individuals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/16/7432?source=related_link\">",
"      Treatment of anti-GBM antibody (Goodpasture's) disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_63_23544="Evaluation of proteinuria in pregnancy";
var content_f22_63_23544=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of proteinuria in pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/63/23544/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/63/23544/contributors\">",
"     Ravi I Thadhani, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/63/23544/contributors\">",
"     Sharon E Maynard, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/63/23544/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/63/23544/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/63/23544/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/63/23544/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/63/23544/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In non-pregnant individuals, abnormal total protein excretion is typically defined as greater than 150 mg daily. In normal pregnancy, urinary protein excretion increases substantially, due to a combination of increased glomerular filtration rate and increased permeability of the glomerular basement membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/1\">",
"     1",
"    </a>",
"    ]. Hence, total protein excretion is considered abnormal in pregnant women when it exceeds 300",
"    <span class=\"nowrap\">",
"     mg/24",
"    </span>",
"    hours [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proteinuria is one of the cardinal features of preeclampsia (",
"    <a class=\"graphic graphic_table graphicRef79977 \" href=\"UTD.htm?4/31/4603\">",
"     table 1",
"    </a>",
"    ), which is a common and potentially severe complication of pregnancy. However, two important points should be noted. First, the severity of proteinuria is not indicative of the severity of preeclampsia and should not be used to guide management [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Second, although part of the formal diagnostic criteria of preeclampsia, proteinuria may be absent. Studies have shown that 10 percent of women with clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histological manifestations of preeclampsia have no proteinuria and 20 percent of women with do not have significant proteinuria prior to their seizure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although less prevalent, primary renal disease and renal disease secondary to systemic disorders, such as diabetes or essential hypertension, are also usually characterized by proteinuria and may first present in pregnancy. To further complicate this picture, 20 to 25 percent of women with chronic hypertension and diabetes develop superimposed preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important for clinicians caring for pregnant women to understand how to identify proteinuria, and how to determine whether preeclampsia or renal disease (or both) is the cause. This topic will discuss the approach to the evaluation of pregnant women with proteinuria. The evaluation of proteinuria in nonpregnant individuals and measurement of protein excretion are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RENAL CHANGES IN NORMAL PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glomerular filtration rate (GFR) and renal blood flow rise markedly during pregnancy, resulting in a physiologic fall in the serum creatinine concentration. As discussed above, urinary protein excretion increases substantially due to a combination of increased GFR and increased permeability of the glomerular basement membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/1\">",
"     1",
"    </a>",
"    ]. Women with uncomplicated twin pregnancies have greater increases in urinary protein excretion than do women with singleton pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/10\">",
"     10",
"    </a>",
"    ]. Additional information on pregnancy-related changes in renal function and the urinary tract can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link\">",
"     \"Renal and urinary tract physiology in normal pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     SCREENING FOR PROTEINURIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine antepartum care includes dipstick protein testing of a random voided urine sample at each prenatal visit. The purpose is detection of preeclampsia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Standard urine dipstick testing is commonly performed on a fresh, clean voided, midstream urine specimen obtained before pelvic examination to minimize the chance of contamination from vaginal secretions. The urinary dipstick for protein is a semi-quantitative colorimetric test that primarily detects albumin. Results range from negative to 4+, corresponding to the following estimates of protein excretion:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Negative",
"     </li>",
"     <li>",
"      Trace - between 15 and 30",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      1+ - between 30 and 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      2+ - between 100 and 300",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      3+ - between 300 and 1000",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      4+ - &gt;1000",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A positive reaction (+1) for protein develops at the threshold concentration of 30",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    which roughly corresponds to a 24-hour urinary protein excretion of 300",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    depending on urine volume.",
"   </p>",
"   <p>",
"    Although inexpensive and commonly used, the urinary dipstick has a high false-positive and false-negative rate when used to screen for abnormal proteinuria in pregnancy, especially at the 1+ level [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/11\">",
"     11",
"    </a>",
"    ]. This is due primarily to variability in urine concentration (osmolality), which can substantially affect random urine protein concentration (ie, the dipstick result) even though there is no change in total daily urinary protein excretion.",
"   </p>",
"   <p>",
"    False positive tests may occur in the presence of gross (macroscopic) blood in the urine, semen, very alkaline urine (pH &gt;7), quaternary ammonium compounds, detergents and disinfectants, drugs, radio-contrast agents, and high specific gravity (&gt;1.030). Positive tests for protein due to blood in the urine seldom exceed 1+ by dipstick. False negatives may occur with low specific gravity (&lt;1.010), high salt concentration, highly acidic urine, or with nonalbumin proteinuria. Despite these limitations, routine urinary dipstick testing remains the mainstay of proteinuria screening in obstetric practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     QUANTIFYING PROTEIN EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary protein can be measured as either albumin or total protein. Non-pregnant women normally excrete less than 30 mg of albumin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/12\">",
"     12",
"    </a>",
"    ] and less than 150 mg of total protein daily. In normal pregnancy, total protein excretion increases to 150 to 250 mg daily [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/2\">",
"     2",
"    </a>",
"    ], and is even higher in twin pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/10\">",
"     10",
"    </a>",
"    ]. Although the mechanism for the increased protein excretion in pregnancy is not established, it seems likely that reabsorption of filtered protein is reduced along with other nonelectrolytes, such as amino acids, glucose, and beta-microglobulin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are two approaches to a definitive quantitative measurement of protein excretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     24-hour collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional method requires a 24-hour urine collection to directly determine the daily total protein or albumin excretion. An extra benefit of this approach, if creatinine is also measured, is that it provides the information necessary to estimate the glomerular filtration rate (GFR) from the creatinine clearance. The 24-hour collection is begun at the usual time the patient awakens. At that time, the first void is discarded and the exact time noted. Subsequently, all urine voids are collected with the last void timed to finish the collection at exactly the same time the next morning. The time of the final urine specimen should vary by no more than 5 or 10 minutes from the time of starting the collection the previous morning. An inexpensive basin urinal that fits into the toilet bowl facilitates collection. The bottle(s) may be kept at normal room temperature for a day or two, but should be kept cool or refrigerated for longer periods of time. No preservatives are needed. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although generally considered the \"gold standard\" for diagnosis of proteinuria in both preeclampsia and renal disease, the 24-hour urine protein excretion in pregnant women is frequently inaccurate due to undercollection or overcollection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, when interpreting the results of a 24-hour urine collection, it is critical to assess the adequacy of collection by quantifying the 24-hour urine creatinine excretion, which is based on muscle mass. The 24-hour urine creatinine excretion should be between 15 and 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    body weight, calculated using pre-pregnancy weight. Values substantially above or below this estimate suggest over- and undercollection, respectively, and should call into question the accuracy of the 24-hour urine protein result.",
"   </p>",
"   <p>",
"    In addition to the high rate of",
"    <span class=\"nowrap\">",
"     inaccurate/incomplete",
"    </span>",
"    collection, the 24-hour urine sample is cumbersome for ambulatory patients, and the result is not available for at least 24 hours while the collection is being completed and analyzed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/13\">",
"     13",
"    </a>",
"    ]. Hence, there has been longstanding interest in alternative methods to quantify urine protein excretion in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Urine protein to creatinine ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spot urine protein-to-creatinine ratio (PC ratio) has become the preferred method for the quantification of proteinuria in the non-pregnant population due to high accuracy, reproducibility, and convenience when compared to timed urine collection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of studies evaluating the urine PC ratio in pregnant women were performed in women with suspected preeclampsia. In these studies, the PC ratio was highly correlated with the 24-hour urine protein measurement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], as it is in non-pregnant adults. Routine bladder catheterization for measurement of urine PC ratio is not necessary; mid-stream clean-catch samples are accurate in pregnant women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over a dozen studies have attempted to validate the urine PC ratio for the detection of abnormal proteinuria in women with hypertensive pregnancy; most used the 24-hour urine collection as the \"gold standard\" [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/16,18-30\">",
"     16,18-30",
"    </a>",
"    ]. Three systematic reviews have evaluated this literature, and came to similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one analysis, the spot urine ratio had a pooled sensitivity of 83.6 percent (95% CI 77.5-89.7) and specificity of 76.3 percent (95% CI 72.6-80.0) using a cut-off of 30 mg",
"      <span class=\"nowrap\">",
"       protein/mmol",
"      </span>",
"      creatinine (0.26 mg",
"      <span class=\"nowrap\">",
"       protein/mg",
"      </span>",
"      creatinine) to predict proteinuria &gt;300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      by 24-hour urine collection [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/32\">",
"       32",
"      </a>",
"      ]. The authors concluded that a low spot protein:creatinine ratio is a reasonable \"rule-out\" test for excluding proteinuria &gt;300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in hypertensive pregnancy.",
"     </li>",
"     <li>",
"      The second analysis suggested that a lower cut-off of 0.13 to 0.15 mg",
"      <span class=\"nowrap\">",
"       protein/mg",
"      </span>",
"      creatinine provides higher (90 to 99 percent) sensitivity, albeit with more false-positive results (specificity 33 to 65 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/33\">",
"       33",
"      </a>",
"      ]. A higher cutoff of 0.6 to 0.7 mg",
"      <span class=\"nowrap\">",
"       protein/mg",
"      </span>",
"      creatinine had a much higher specificity (96 percent) for significant proteinuria (&gt;300 mg in a 24-hour specimen), but at the cost of lower sensitivity (85 to 87 percent). Midrange",
"      <span class=\"nowrap\">",
"       protein/creatinine",
"      </span>",
"      ratios (0.3 mg",
"      <span class=\"nowrap\">",
"       protein/mg",
"      </span>",
"      creatinine) had poor sensitivity and specificity.",
"     </li>",
"     <li>",
"      A third meta-analysis, including 2790 women from 15 studies, had similar findings: a single diagnostic threshold of approximately 0.30 mg",
"      <span class=\"nowrap\">",
"       protein/mg",
"      </span>",
"      creatinine had a sensitivity and specificity of 81 and 76 percent, respectively, for the detection of &gt;300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      proteinuria by 24-hour urine collection [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/34\">",
"       34",
"      </a>",
"      ]. A lower cut-off (0.13",
"      <span class=\"nowrap\">",
"       mg/mg)",
"      </span>",
"      had better (89 percent) sensitivity for the exclusion of proteinuria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these data suggest that a urine PC ratio above 0.7 mg",
"    <span class=\"nowrap\">",
"     protein/mg",
"    </span>",
"    creatinine strongly predicts significant proteinuria while a urine PC ratio less than 0.15 mg",
"    <span class=\"nowrap\">",
"     protein/mg",
"    </span>",
"    creatinine can be considered normal (predictive of less than 300 mg protein in a 24-hour collection), so confirmatory testing with 24-hour urine collection probably isn't necessary in these individuals. Women with urine PC ratio results between 0.15 and 0.7 mg",
"    <span class=\"nowrap\">",
"     protein/mg",
"    </span>",
"    creatinine should have a 24-hour urine collection to accurately quantify proteinuria. If a 24 hour urine collection is not obtained, guidelines define proteinuria as random urine sample PC ratio &ge;0.26 mg",
"    <span class=\"nowrap\">",
"     protein/mg",
"    </span>",
"    creatinine (30",
"    <span class=\"nowrap\">",
"     mg/mmol)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Urine albumin to creatinine ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urine albumin:creatinine ratio (ACR), like the PC ratio, is measured using a random \"spot\" urine specimen. Originally developed for the detection of albuminuria in patients with diabetes mellitus, the ACR is now recommended as the best initial screening test for proteinuria in non-pregnant adults, due to its increased sensitivity as compared with the PC ratio. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ACR also has the advantage that it can be performed using an automated analyzer, allowing immediate point-of-care testing that could be utilized in an antenatal clinic. Like the PC ratio, the ACR (using a threshold of between 2.5 and 8.0",
"    <span class=\"nowrap\">",
"     mg/mmol)",
"    </span>",
"    is strongly predictive of significant proteinuria in a high-risk obstetric antenatal clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/28,36\">",
"     28,36",
"    </a>",
"    ] and in women with hypertensive pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In one study, women with a spot urine ACR &gt;35.5",
"    <span class=\"nowrap\">",
"     mg/mmol",
"    </span>",
"    measured at 17 to 20 weeks of gestation were at almost eight-fold higher risk of subsequently developing preeclampsia (relative risk [RR] 7.8) compared with women with ACR &lt;35.5",
"    <span class=\"nowrap\">",
"     mg/mmol",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/39\">",
"     39",
"    </a>",
"    ]. Although more data are needed, the spot ACR has the potential to supplant urinary dipstick as a rapid and accurate screening method for proteinuria in routine obstetric care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2862820\">",
"    <span class=\"h2\">",
"     8- or 12-hour collection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies suggest that measurement of protein in an 8-hour [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/40\">",
"     40",
"    </a>",
"    ] or 12-hour [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/41\">",
"     41",
"    </a>",
"    ] urine collection may be a reasonable alternative to the 24-hour urine collection for quantification of proteinuria. For example, in one study, excretion of &gt;165 mg proteinuria in a 12-hour collection was highly predictive (96 percent sensitivity, 100 percent specificity) of 24-hour proteinuria &gt;300 mg, markedly outperforming the spot urine protein:creatinine ratio (89 percent sensitivity, 49 percent specificity for spot urine protein:creatinine ratio &gt;0.15",
"    <span class=\"nowrap\">",
"     mg/mg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS OF PROTEINURIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal disease versus preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the evaluation of a pregnant patient with proteinuria, the first consideration is to determine whether the proteinuria is due to preeclampsia or some other renal disease, whether pre-existing or de novo (",
"    <a class=\"graphic graphic_table graphicRef67810 \" href=\"UTD.htm?35/14/36075\">",
"     table 2",
"    </a>",
"    ). In patients with established renal disease before conception or in whom proteinuria is documented before the 20th week of gestation, the diagnosis of pre-existing renal disease can be readily made because preeclampsia rarely occurs before that time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=see_link\">",
"     \"Pregnancy in women with underlying renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Conversely, the clear documentation of new-onset proteinuria after 20 weeks of gestation, especially when accompanied by new-onset hypertension, strongly suggests preeclampsia. However, de novo renal disease (for example, lupus nephritis) can sometimes occur during late pregnancy, as well. When information on the presence of proteinuria (and hypertension) in early pregnancy is lacking, distinguishing between underlying renal disease and preeclampsia can be difficult. For this reason, it is useful to quantify protein excretion in early pregnancy in women at risk for underlying renal disease (ie, women with chronic hypertension, diabetes mellitus, and systemic lupus erythematosus). Diagnostic evaluation in women when the etiology of proteinuria is unclear should include renal ultrasound, as urinary tract dilatation has been associated with proteinuria in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A novel serum test for early diagnosis of preeclampsia has been developed, which relies on detection of abnormal levels of placentally-derived angiogenic factors, sFlt1 (soluble fms-like tyrosine kinase-1) and PlGF (placental growth factor) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/43\">",
"     43",
"    </a>",
"    ]. This diagnostic test is available in Europe (Roche Diagnostics, Rotkreuz, Switzerland) and is being evaluated by the FDA for use in the United States. Although more studies are needed to validate its use, this serum test may prove useful and cost-effective in distinguishing preeclampsia from other causes of proteinuria in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/44,45\">",
"     44,45",
"    </a>",
"    ], and appears to be predictive of adverse maternal and neonatal outcomes in women with clinical suspicion of preeclampsia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathogenesis of preeclampsia\", section on 'sFlt-1, VEGF, PIGF'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The distinction between renal disease and preeclampsia is important because it affects clinical management. In patients with renal disease, the usual aim is term delivery, while patients with preeclampsia often develop progressive disease culminating in the need for iatrogenic preterm delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=see_link\">",
"     \"Pregnancy in women with underlying renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In instances where the distinction between renal disease and preeclampsia cannot be resolved, it is prudent to assume preeclampsia as the working diagnosis, as it has the potential for rapid development of serious maternal and fetal complications.",
"   </p>",
"   <p>",
"    In some cases, the distinction between renal disease and preeclampsia can only be made in retrospect, as clinical signs of preeclampsia generally resolve within 12 weeks after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/48\">",
"     48",
"    </a>",
"    ], while proteinuria due to underlying renal disease does not. However, resolution of proteinuria after preeclampsia, especially when severe, can sometimes take much longer. In one cohort study of 205 women with preeclampsia, 14 percent had persistent proteinuria at 12 weeks after delivery, which resolved by two years postpartum in all but 2 percent of subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/49\">",
"     49",
"    </a>",
"    ]. Nevertheless, proteinuria (or hypertension) which persists longer than three months after delivery should prompt close follow-up and consideration of further evaluation and appropriate referral, so that underlying renal disease or chronic hypertension is detected and treated expeditiously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Superimposed preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;When preeclampsia develops in women with preexisting renal disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypertension, it often occurs earlier in gestation and may be particularly severe. In such cases, significant clues to the diagnosis of superimposed preeclampsia can be provided by the systemic manifestations of the disorder, if present, such as thrombocytopenia, an increase in levels of liver enzymes, hemolysis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    evidence of fetal compromise (including intrauterine growth restriction) (",
"    <a class=\"graphic graphic_table graphicRef60502 \" href=\"UTD.htm?17/15/17659\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternatively, worsening hypertension and proteinuria in a woman with renal disease may represent an exacerbation of the underlying disease. Studies in women with documented primary renal disease predating pregnancy have demonstrated that the majority of women with glomerular disease exhibit increasing proteinuria during the course of their gestation and nephrotic syndrome in the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis for hypertension and proteinuria in pregnancy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=see_link&amp;anchor=H19#H19\">",
"     \"Preeclampsia: Clinical features and diagnosis\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nephrotic-range proteinuria (&gt;3.0",
"    <span class=\"nowrap\">",
"     g/24",
"    </span>",
"    hours) is a sign of glomerular injury. Pathology limited to the renal tubules and interstitium typically results in protein excretion rates less than 2.0",
"    <span class=\"nowrap\">",
"     g/24",
"    </span>",
"    hours unless glomerular disease is also present. Patients with protein excretion less than 3.0",
"    <span class=\"nowrap\">",
"     g/24",
"    </span>",
"    hours are usually asymptomatic. In contrast, rates greater than 3.0",
"    <span class=\"nowrap\">",
"     g/24",
"    </span>",
"    hours may cause the nephrotic syndrome, which consists of nephrotic-range proteinuria together with edema, hypoalbuminemia, and hyperlipidemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=see_link\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severe preeclampsia is the most common cause of de novo nephrotic syndrome in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/53\">",
"     53",
"    </a>",
"    ]. However, the nephrotic syndrome in pregnancy may also be caused by preexisting renal disease (which is often accompanied by a large increase in proteinuria during pregnancy), and de novo renal disease that develops during pregnancy (eg, associated with invasive trophoblastic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/54\">",
"     54",
"    </a>",
"    ]). Once it has been determined that the patient has heavy proteinuria, the etiology may be suggested from the history and physical examination. This is particularly true for patients who have a systemic disease such as diabetes mellitus, systemic lupus erythematosus, HIV infection, or intake of a commonly offending drug although this is much less common in pregnant women (NSAIDs, gold,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    ). In most cases, however, renal biopsy is required to establish the diagnosis.",
"   </p>",
"   <p>",
"    If de novo renal disease is suspected as the cause of nephrotic syndrome, a renal biopsy during pregnancy is an option for definitive diagnosis if the patient's management would be affected, but this is rare. Several analyses have concluded that the presence of nephrotic syndrome due to renal disease, in the absence of significant renal insufficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    significant hypertension, does not seem to affect the natural course of renal disease or fetal survival [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although data on the safety of renal biopsy during pregnancy are limited, clinical experience suggests that it is technically easier if undertaken prior to about 30 weeks of gestation. Later in gestation, the gravid uterus makes the standard prone position difficult. In such cases, renal biopsy is frequently deferred until the patient has stabilized postpartum. The major complication of biopsy is bleeding. In a systematic review of reports of renal biopsies performed during pregnancy or postpartum, the risk of bleeding appeared to be higher when the biopsy was performed during pregnancy (7 percent",
"    <span class=\"nowrap\">",
"     [16/197]",
"    </span>",
"    versus 1 percent",
"    <span class=\"nowrap\">",
"     [3/268])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/56\">",
"     56",
"    </a>",
"    ]. All observed cases of major bleeding (ie, requiring blood transfusion) occurred in biopsies performed between 23 to 26 weeks of gestation, suggesting women in this gestational age range may be particularly vulnerable to complications.",
"   </p>",
"   <p>",
"    The management of the nephrotic syndrome in pregnancy is based on expert opinion, as very little data are available to support evidence-based practice. Management typically aims to reduce edema to a level that allows comfort during ambulation. The dietary intake of sodium may be limited to 1.5 g of sodium per day (approximately 60 mEq) to reduce new edema formation, provided normal blood pressure is maintained. Bed rest is a safe and often effective method to facilitate resolution of edema.",
"   </p>",
"   <p>",
"    In general, the use of diuretics is discouraged because of the theoretical risk that they will impair the normal pregnancy-associated expansion of plasma volume, possibly decreasing placental perfusion. However, there is no clear evidence of adverse fetal effects with either thiazide or loop diuretics, and their use is occasionally indicated for severe, intractable edema [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23544/abstract/57\">",
"     57",
"    </a>",
"    ]. In such cases, therapy should aim to reduce excessive edema at a slow rate of no more than 1 to 2 pounds per day with a loop diuretic, while a low sodium diet is maintained. If treatment on a chronic basis is needed, diuretic therapy should be administered on an alternate-day schedule to avoid a reduction of plasma volume and electrolyte disturbances. A written record of daily weights, taken by the patient, is highly recommended. Diuretics should not be used in preeclampsia because this condition is characterized by a reduction in circulating plasma volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=see_link\">",
"       \"Patient information: Protein in the urine (proteinuria) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation of a fresh midstream urine specimen obtained as a clean voided specimen before pelvic examination minimizes the chance of contamination from vaginal secretions. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Screening for proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urine dipstick to screen for proteinuria is associated with frequent false-positive and false-negative results, especially when the urine is particularly concentrated or dilute, respectively. It is most predictive of abnormal 24-hour proteinuria if +2 or greater. Positive urine dipsticks should be followed-up with a quantitative test. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Screening for proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The urinary protein-to-creatinine (PC) ratio (mg",
"      <span class=\"nowrap\">",
"       protein/mg",
"      </span>",
"      creatinine) is an accurate, convenient, and relatively rapid method to quantify proteinuria in pregnancy. A urine PC ratio less than 0.15",
"      <span class=\"nowrap\">",
"       mg/mg",
"      </span>",
"      may be considered normal (predictive of less than 300 mg protein in a 24-hour collection) and values above 0.7",
"      <span class=\"nowrap\">",
"       mg/mg",
"      </span>",
"      are very likely to indicate significant proteinuria (more than 300 mg protein in a 24-hour collection). Ratios between 0.15 and 0.7",
"      <span class=\"nowrap\">",
"       mg/mg",
"      </span>",
"      should be further evaluated by 24-hour urine collection. If a 24 hour urine collection is not obtained, a protein:creatinine ratio of 0.26",
"      <span class=\"nowrap\">",
"       mg/mg",
"      </span>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/mmol)",
"      </span>",
"      in a random urine sample is suggested as the threshold for significant proteinuria. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Quantifying protein excretion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The gestational age at which proteinuria is first documented is important in establishing the likelihood of preeclampsia versus other renal disease. Proteinuria documented prior to pregnancy or in early pregnancy (before 20 weeks of gestation) suggests preexisting renal disease. In late pregnancy, the presence of hypertension or other",
"      <span class=\"nowrap\">",
"       signs/symptoms",
"      </span>",
"      of severe preeclampsia (eg, thrombocytopenia, elevated liver transaminases), if present, also helps to distinguish preeclampsia from underlying renal disease. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis of proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preeclampsia is the most common cause of proteinuria in pregnancy and",
"      <strong>",
"       must be excluded",
"      </strong>",
"      in all women with proteinuria first identified after 20 weeks of gestation. If preeclampsia is excluded, then the presence of primary or secondary renal disease should be considered. If renal biopsy is indicated for diagnosis, it is usually better to wait until the patient is postpartum unless unexplained rapidly progressive loss of renal function is occurring. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis of proteinuria'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/1\">",
"      Roberts M, Lindheimer MD, Davison JM. Altered glomerular permselectivity to neutral dextrans and heteroporous membrane modeling in human pregnancy. Am J Physiol 1996; 270:F338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/2\">",
"      Higby K, Suiter CR, Phelps JY, et al. Normal values of urinary albumin and total protein excretion during pregnancy. Am J Obstet Gynecol 1994; 171:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/3\">",
"      Lindheimer MD, Kanter D. Interpreting abnormal proteinuria in pregnancy: the need for a more pathophysiological approach. Obstet Gynecol 2010; 115:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/4\">",
"      von Dadelszen P, Payne B, Li J, et al. Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model. Lancet 2011; 377:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/5\">",
"      Payne B, Magee LA, C&ocirc;t&eacute; AM, et al. PIERS proteinuria: relationship with adverse maternal and perinatal outcome. J Obstet Gynaecol Can 2011; 33:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/6\">",
"      Thornton CE, Makris A, Ogle RF, et al. Role of proteinuria in defining pre-eclampsia: clinical outcomes for women and babies. Clin Exp Pharmacol Physiol 2010; 37:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/7\">",
"      Sibai BM. Eclampsia. VI. Maternal-perinatal outcome in 254 consecutive cases. Am J Obstet Gynecol 1990; 163:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/8\">",
"      Sibai BM, Lindheimer M, Hauth J, et al. Risk factors for preeclampsia, abruptio placentae, and adverse neonatal outcomes among women with chronic hypertension. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998; 339:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/9\">",
"      Ros HS, Cnattingius S, Lipworth L. Comparison of risk factors for preeclampsia and gestational hypertension in a population-based cohort study. Am J Epidemiol 1998; 147:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/10\">",
"      Smith NA, Lyons JG, McElrath TF. Protein:creatinine ratio in uncomplicated twin pregnancy. Am J Obstet Gynecol 2010; 203:381.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/11\">",
"      Waugh JJ, Clark TJ, Divakaran TG, et al. Accuracy of urinalysis dipstick techniques in predicting significant proteinuria in pregnancy. Obstet Gynecol 2004; 103:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/12\">",
"      Viberti GC, Jarrett RJ, Keen H. Microalbuminuria as prediction of nephropathy in diabetics. Lancet 1982; 2:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/13\">",
"      C&ocirc;t&eacute; AM, Firoz T, Mattman A, et al. The 24-hour urine collection: gold standard or historical practice? Am J Obstet Gynecol 2008; 199:625.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/14\">",
"      Eknoyan G, Hostetter T, Bakris GL, et al. Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 2003; 42:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/15\">",
"      Robert M, Sepandj F, Liston RM, Dooley KC. Random protein-creatinine ratio for the quantitation of proteinuria in pregnancy. Obstet Gynecol 1997; 90:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/16\">",
"      Neithardt AB, Dooley SL, Borensztajn J. Prediction of 24-hour protein excretion in pregnancy with a single voided urine protein-to-creatinine ratio. Am J Obstet Gynecol 2002; 186:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/17\">",
"      Chen BA, Parviainen K, Jeyabalan A. Correlation of catheterized and clean catch urine protein/creatinine ratios in preeclampsia evaluation. Obstet Gynecol 2008; 112:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/18\">",
"      Rodriguez-Thompson D, Lieberman ES. Use of a random urinary protein-to-creatinine ratio for the diagnosis of significant proteinuria during pregnancy. Am J Obstet Gynecol 2001; 185:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/19\">",
"      Young RA, Buchanan RJ, Kinch RA. Use of the protein/creatinine ratio of a single voided urine specimen in the evaluation of suspected pregnancy-induced hypertension. J Fam Pract 1996; 42:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/20\">",
"      Ramos JG, Martins-Costa SH, Mathias MM, et al. Urinary protein/creatinine ratio in hypertensive pregnant women. Hypertens Pregnancy 1999; 18:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/21\">",
"      Saudan PJ, Brown MA, Farrell T, Shaw L. Improved methods of assessing proteinuria in hypertensive pregnancy. Br J Obstet Gynaecol 1997; 104:1159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/22\">",
"      Jaschevatzky OE, Rosenberg RP, Shalit A, et al. Protein/creatinine ratio in random urine specimens for quantitation of proteinuria in preeclampsia. Obstet Gynecol 1990; 75:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/23\">",
"      Durnwald C, Mercer B. A prospective comparison of total protein/creatinine ratio versus 24-hour urine protein in women with suspected preeclampsia. Am J Obstet Gynecol 2003; 189:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/24\">",
"      Al RA, Baykal C, Karacay O, et al. Random urine protein-creatinine ratio to predict proteinuria in new-onset mild hypertension in late pregnancy. Obstet Gynecol 2004; 104:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/25\">",
"      Wheeler TL 2nd, Blackhurst DW, Dellinger EH, Ramsey PS. Usage of spot urine protein to creatinine ratios in the evaluation of preeclampsia. Am J Obstet Gynecol 2007; 196:465.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/26\">",
"      Aggarwal N, Suri V, Soni S, et al. A prospective comparison of random urine protein-creatinine ratio vs 24-hour urine protein in women with preeclampsia. Medscape J Med 2008; 10:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/27\">",
"      Dwyer BK, Gorman M, Carroll IR, Druzin M. Urinalysis vs urine protein-creatinine ratio to predict significant proteinuria in pregnancy. J Perinatol 2008; 28:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/28\">",
"      Kyle PM, Fielder JN, Pullar B, et al. Comparison of methods to identify significant proteinuria in pregnancy in the outpatient setting. BJOG 2008; 115:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/29\">",
"      Lea&ntilde;os-Miranda A, M&aacute;rquez-Acosta J, Romero-Arauz F, et al. Protein:creatinine ratio in random urine samples is a reliable marker of increased 24-hour protein excretion in hospitalized women with hypertensive disorders of pregnancy. Clin Chem 2007; 53:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/30\">",
"      Yamasmit W, Chaithongwongwatthana S, Charoenvidhya D, et al. Random urinary protein-to-creatinine ratio for prediction of significant proteinuria in women with preeclampsia. J Matern Fetal Neonatal Med 2004; 16:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/31\">",
"      Stout MJ, Scifres CM, Stamilio DM. Diagnostic utility of urine protein-to-creatinine ratio for identifying proteinuria in pregnancy. J Matern Fetal Neonatal Med 2013; 26:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/32\">",
"      C&ocirc;t&eacute; AM, Brown MA, Lam E, et al. Diagnostic accuracy of urinary spot protein:creatinine ratio for proteinuria in hypertensive pregnant women: systematic review. BMJ 2008; 336:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/33\">",
"      Papanna R, Mann LK, Kouides RW, Glantz JC. Protein/creatinine ratio in preeclampsia: a systematic review. Obstet Gynecol 2008; 112:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/34\">",
"      Morris RK, Riley RD, Doug M, et al. Diagnostic accuracy of spot urinary protein and albumin to creatinine ratios for detection of significant proteinuria or adverse pregnancy outcome in patients with suspected pre-eclampsia: systematic review and meta-analysis. BMJ 2012; 345:e4342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/35\">",
"      Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ 2010; 341:c2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/36\">",
"      Wilkinson C, Lappin D, Vellinga A, et al. Spot urinary protein analysis for excluding significant proteinuria in pregnancy. J Obstet Gynaecol 2013; 33:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/37\">",
"      Nisell H, Trygg M, B&auml;ck R. Urine albumin/creatinine ratio for the assessment of albuminuria in pregnancy hypertension. Acta Obstet Gynecol Scand 2006; 85:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/38\">",
"      Gangaram R, Naicker M, Moodley J. Comparison of pregnancy outcomes in women with hypertensive disorders of pregnancy using 24-hour urinary protein and urinary microalbumin to creatinine ratio. Int J Gynaecol Obstet 2009; 107:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/39\">",
"      Baweja S, Kent A, Masterson R, et al. Prediction of pre-eclampsia in early pregnancy by estimating the spot urinary albumin: creatinine ratio using high-performance liquid chromatography. BJOG 2011; 118:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/40\">",
"      Khazardoost S, Abdollahi A, Shafaat M. Comparison of 8-h urine protein and random urinary protein-to-creatinine ratio with 24-h urine protein in pregnancy. J Matern Fetal Neonatal Med 2012; 25:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/41\">",
"      Tun C, Qui&ntilde;ones JN, Kurt A, et al. Comparison of 12-hour urine protein and protein:creatinine ratio with 24-hour urine protein for the diagnosis of preeclampsia. Am J Obstet Gynecol 2012; 207:233.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/42\">",
"      Piccoli GB, Attini R, Parisi S, et al. Excessive urinary tract dilatation and proteinuria in pregnancy: a common and overlooked association? BMC Nephrol 2013; 14:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/43\">",
"      Verlohren S, Galindo A, Schlembach D, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010; 202:161.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/44\">",
"      Sunderji S, Gaziano E, Wothe D, et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol 2010; 202:40.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/45\">",
"      Hadker N, Garg S, Costanzo C, et al. Financial impact of a novel pre-eclampsia diagnostic test versus standard practice: a decision-analytic modeling analysis from a UK healthcare payer perspective. J Med Econ 2010; 13:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/46\">",
"      Moore AG, Young H, Keller JM, et al. Angiogenic biomarkers for prediction of maternal and neonatal complications in suspected preeclampsia. J Matern Fetal Neonatal Med 2012; 25:2651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/47\">",
"      Rana S, Powe CE, Salahuddin S, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012; 125:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/48\">",
"      Chua S, Redman CW. Prognosis for pre-eclampsia complicated by 5 g or more of proteinuria in 24 hours. Eur J Obstet Gynecol Reprod Biol 1992; 43:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/49\">",
"      Berks D, Steegers EA, Molas M, Visser W. Resolution of hypertension and proteinuria after preeclampsia. Obstet Gynecol 2009; 114:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/50\">",
"      ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 77:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/51\">",
"      Katz AI, Davison JM, Hayslett JP, et al. Pregnancy in women with kidney disease. Kidney Int 1980; 18:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/52\">",
"      Reece EA, Coustan DR, Hayslett JP, et al. Diabetic nephropathy: pregnancy performance and fetomaternal outcome. Am J Obstet Gynecol 1988; 159:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/53\">",
"      Fisher KA, Luger A, Spargo BH, Lindheimer MD. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine (Baltimore) 1981; 60:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/54\">",
"      Yang JW, Choi SO, Kim BR, et al. Nephrotic syndrome associated with invasive mole: a case report. Nephrol Dial Transplant 2010; 25:2023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/55\">",
"      Strauch BS, Hayslett JP. Kidney disease and pregnancy. Br Med J 1974; 4:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/56\">",
"      Piccoli GB, Daidola G, Attini R, et al. Kidney biopsy in pregnancy: evidence for counselling? A systematic narrative review. BJOG 2013; 120:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23544/abstract/57\">",
"      Collins R, Yusuf S, Peto R. Overview of randomised trials of diuretics in pregnancy. Br Med J (Clin Res Ed) 1985; 290:17.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4808 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-122.72.76.133-2ED33AB258-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23544=[""].join("\n");
var outline_f22_63_23544=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RENAL CHANGES IN NORMAL PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      SCREENING FOR PROTEINURIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      QUANTIFYING PROTEIN EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      24-hour collection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Urine protein to creatinine ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Urine albumin to creatinine ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2862820\">",
"      8- or 12-hour collection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIFFERENTIAL DIAGNOSIS OF PROTEINURIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal disease versus preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Superimposed preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4808\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4808|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/31/4603\" title=\"table 1\">",
"      Criteria for preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/14/36075\" title=\"table 2\">",
"      Causes of proteinuria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/15/17659\" title=\"table 3\">",
"      Findings that increase the certainty of dx of preeclampsia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/61/34777?source=related_link\">",
"      Pathogenesis of preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/35/15921?source=related_link\">",
"      Patient information: Protein in the urine (proteinuria) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11241?source=related_link\">",
"      Pregnancy in women with underlying renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_63_23545="MRI HSV encephalitis";
var content_f22_63_23545=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    MRI findings in a patient with herpes simplex encephalitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 616px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (Upper panels) Magnetic resonance (MR) images of the brain of a patient with herpes simplex virus encephalitis at two day after admission. Abnormal signals were seen in the right temporal lobe and insular cortex.",
"    <br/>",
"    (Lower panels) MR images showing that abnormal signals had spread to the left side at 15 days after admission.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Department of Neurology, Obihiro Kosei General Hospital, Obihiro. Received for publication March 24, 2003. Copyright &copy; Hideki Houzen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23545=[""].join("\n");
var outline_f22_63_23545=null;
var title_f22_63_23546="HLA and other susceptibility genes in rheumatoid arthritis";
var content_f22_63_23546=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   HLA and other susceptibility genes in rheumatoid arthritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/63/23546/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/63/23546/contributors\">",
"     Anne Barton, MRCP, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/63/23546/contributors\">",
"     Soumya Raychaudhuri, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/63/23546/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/63/23546/contributors\">",
"     RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/63/23546/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/63/23546/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/63/23546/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The association of the human leukocyte antigen (HLA) region with rheumatoid arthritis (RA) was first noted in the late 1970s when the frequency of individuals with the HLA-Dw4 serotype was found to be increased among RA patients compared with healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This particular serotype bound a set of alleles at the HLA-DRB1 gene. Subsequently, hundreds of studies have examined and expanded that association in order to better elucidate the genetic underpinnings of rheumatoid arthritis.",
"   </p>",
"   <p>",
"    Both linkage and association studies of the HLA-DRB1 gene have consistently confirmed that it is the major genetic susceptibility locus for RA. As such, it provides an important clue to pathogenesis. Subsequent discoveries using high-throughput genotyping have identified over 40 additional loci outside of the HLA locus that play a relatively modest role in rheumatoid arthritis risk but that implicate critical pathways in pathogenesis. However, the issue of clinical utility of genotyping in patients with RA remains unresolved.",
"   </p>",
"   <p>",
"    This topic will address the role of HLA and other susceptibility genes in rheumatoid arthritis. The epidemiology of, risk factors for, causes of, and pathogenesis of RA, as well as an overview of HLA genes and their nomenclature, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39593?source=see_link\">",
"     \"Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=see_link\">",
"     \"Pathogenesis of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HLA CLASS II ASSOCIATIONS IN RHEUMATOID ARTHRITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpretation of early studies of HLA associations in RA has been complicated by evolving changes in nomenclature and methods of typing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/3\">",
"     3",
"    </a>",
"    ]. Modern methods of HLA typing involve amplification by the polymerase chain reaction of the highly polymorphic second exon of the HLA-DRB1 gene, followed by probing with a DNA sequence-specific oligonucleotide probe. Direct nucleotide sequencing is an alternative method of genotyping. The DR4 &ldquo;family&rdquo; of alleles contains at least 22 members, only some of which are associated with RA. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=see_link\">",
"     \"Human leukocyte antigens (HLA): A roadmap\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Individual alleles and the shared epitope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two alleles, DRB1*0401 and DRB1*0404, primarily account for the originally observed serological association of DR4 with disease in Caucasians. In addition, serological associations with DR1 have been noted in many Caucasian RA patients who are negative for DR4. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Associations in different ethnic populations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The most strongly associated RA alleles share a region of highly similar amino acid sequence, called the shared epitope (QKRAA, QRRAA, or RRRAA). It had been postulated that this portion of the DRB1 molecule (amino acids 67 to 74) controls susceptibility to disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/4\">",
"     4",
"    </a>",
"    ]. This hypothesis has been further bolstered by the remarkable finding that, among ethnic populations in which DR4 is rare, the alleles associated with RA still contain the shared epitope. As an example, some Native American populations, such as the Yakima Nation, have a high prevalence of RA. DR4 alleles are rare in this population, and RA is associated with a DR6 allele (DRB1*1402). Sequencing of this allele reveals that the region of the molecule encompassing amino acids 67 to 74 is identical to the shared epitope [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/5\">",
"     5",
"    </a>",
"    ]. Importantly, the shared epitope association is specific to RA patients with anti-citrullinated peptide antibodies (ACPA) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The strength of the association of particular HLA susceptibility alleles with RA varies in different studies. To some degree, this variability is due to differences in the criteria for inclusion of patients, in genetic backgrounds of the populations studied, and in the HLA typing methods used. However, a remarkable degree of consensus emerges when these variables are controlled. If, for example, only Caucasian patients are included and if the HLA typing is DNA-based, then similar results have been obtained in different reports [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HLA-DRB1*0401 &mdash; present in 50 to 61 percent with a relative risk of 5 to 11",
"     </li>",
"     <li>",
"      HLA-DRB1*0404 &mdash; present in 27 to 37 percent with a relative risk of 5 to 14. One report, however, found this allele to be present in only 9 percent with a relative risk of 1. In another report, an increased risk of RA was noted when there were two copies of the HLA-DRB1*0404 allele or when it was present along with another gene encoding the shared epitope [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      HLA-DRB1*0101 &mdash; present in 13 to 27 percent with a relative risk of 1 to 2",
"     </li>",
"     <li>",
"      HLA-DRB1*10 &mdash; present in 1.5 percent of RA patients with a relative risk of 2.3 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Associations in different ethnic populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data have accumulated on HLA associations with RA in diverse ethnic populations, many of which display a very different genetic background from Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/11\">",
"     11",
"    </a>",
"    ]. Nevertheless, the vast majority of these studies confirm a significant increase in the frequency of alleles containing the shared epitope in RA patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among normal Japanese, the most prevalent DR4 allele is DRB1*0405, which contains the shared epitope and which is increased in patients with RA [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Both DRB1*0405 and 0404 are increased in Chinese patients [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DRB1*1402 confers susceptibility to RA in the Yakima, Tlingit, and Pima Native American populations [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/5,14,15\">",
"       5,14,15",
"      </a>",
"      ]. The DR4 specificity is also present in the Chippewa Indians [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In some populations, such as the Spanish, Basque, and Israeli populations, DR4 alleles are rare. In these settings, RA is associated with DR1 or DR10, two other alleles carrying the shared epitope [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other populations, such as African Americans, the majority of patients with RA do not carry the shared epitope in their DRB1 genes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/21\">",
"     21",
"    </a>",
"    ]. Even in this study, however, DR4-positive (DR4+) susceptibility alleles were significantly increased among rheumatoid factor (RF)-positive patients. A similar observation was made in a study of Greek patients with RA; although 57 percent lacked the shared epitope, its presence was still significantly increased compared with local controls (43 versus 15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3320096\">",
"    <span class=\"h2\">",
"     Protective HLA alleles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some HLA-DRB1 alleles may protect against the development of RA rather than enhance the risk [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/23\">",
"     23",
"    </a>",
"    ]. As an example, the presence of an aspartic acid (versus glutamine or arginine) at the 70th amino acid position results in an odds ratio (OR) of 0.23 and 0.34 for RA among English and Spanish populations, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/24\">",
"     24",
"    </a>",
"    ] and in an OR of 0.52 among a North American population. This allele also nullified the effect of an otherwise risk-enhancing allele on the sister chromosome.",
"   </p>",
"   <p>",
"    Protective alleles were also found in another study, in which the net charge of amino acids forming one of the peptide binding pockets (p4) of the HLA class II molecule was predicted from the sequence of the corresponding HLA-DR1 alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/25\">",
"     25",
"    </a>",
"    ]; a net neutral or negative charge was associated with a significantly reduced risk of RA. All but one of the 20 alleles with a neutral or negatively charged pocket encoded an aspartic acid at position 70 of the DB beta 1 protein.",
"   </p>",
"   <p>",
"    Homology among HLA-DRB1 alleles that are associated with a reduced risk of RA has been noted. In addition to the presence of aspartic acid at position 70, noted above, the presence of isoleucine at position 67 is associated with a protective effect [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some evidence suggests that a protective allele, when present in the mother, may reduce the risk of RA in her child, when the allele is absent in her child [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/27\">",
"     27",
"    </a>",
"    ]. This phenomenon, referred to as a protective effect of non-inherited maternal antigens, is supported by the finding of a reduced risk of RA in offspring when protective alleles are present in mothers versus fathers. The mechanism underlying the protective effect is uncertain. Transplacental transfer of long-lived maternal cells bearing the protective HLA antigens to the child, a phenomenon referred to as microchimerism, is an attractive but unproven explanation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4298962\">",
"    <span class=\"h2\">",
"     Individual amino acid sites and rheumatoid arthritis risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large study of 20,000 individuals has demonstrated that individual amino acid sites within the HLA-DRB1 explain rheumatoid arthritis risk susceptibility most effectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/28\">",
"     28",
"    </a>",
"    ]. In particular, position 11, sitting at the base of the DRB1 binding groove, modulates risk; the presence of a valine at that site confers an allelic odds ration of approximately 4, whereas the presence of a serine corresponds to an allelic odds ratio of 0.4. Additionally, positions 71 and 74 (located within the shared epitope consensus sequence), also pointing into the antigen binding groove, modulate disease risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HLA ALLELES AND SEVERITY OF RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ongoing question pertains to whether certain alleles confer disease severity or susceptibility. Most [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/29-31\">",
"     29-31",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/32-34\">",
"     32-34",
"    </a>",
"    ], studies have found a correlation between DR4+ RA-associated alleles and more severe, erosive disease, as measured by the severity of radiographic changes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/29-31,35,36\">",
"     29-31,35,36",
"    </a>",
"    ]; some also note an increase in DR1 among patients with milder disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This association between DR4+ alleles and erosive disease is confirmed among non-Caucasian patients, including Koreans [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/37\">",
"     37",
"    </a>",
"    ] and Japanese [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/38\">",
"     38",
"    </a>",
"    ]. In 2004, a meta-analysis of the impact of shared epitope positive alleles on erosive disease summarized the results of 10 studies (1027 patients) and found that carriage of one or two such alleles was associated with an odds ratio of about 2 of having joint erosion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It remains unclear whether this observation indicates that expressing a DR4+ allele that contains the shared epitope increases the risk for developing RA in the first place or increases the risk of progressing to severe, erosive RA once the disease has occurred. It is probably most useful to think of the DR4+ disease-associated alleles as conferring susceptibility to severe disease, with two copies conferring a higher risk than one copy.",
"   </p>",
"   <p>",
"    The specific combination of shared epitope-positive alleles also appears to be important. The DR4+ alleles confer a greater risk of RA than non-DR4 alleles with the shared epitope, such as DR1. One report evaluated a large group of patients with severe RA, including many with Felty&rsquo;s syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/40\">",
"     40",
"    </a>",
"    ]. A hierarchy of risk was found, depending upon the particular combination of DR alleles: the relative risk was 5 with the heterozygous",
"    <span class=\"nowrap\">",
"     DR4/X",
"    </span>",
"    combination (where X is any allele other than DR4 or DR1); 16 with",
"    <span class=\"nowrap\">",
"     DR4/DR1;",
"    </span>",
"    25 with",
"    <span class=\"nowrap\">",
"     DR4/DR4",
"    </span>",
"    combinations; and 49 with",
"    <span class=\"nowrap\">",
"     HLA-DRB1*0401/0404",
"    </span>",
"    <span class=\"nowrap\">",
"     (Dw4/Dw14).",
"    </span>",
"   </p>",
"   <p>",
"    The presence of a shared epitope in a DR4+ allele may predispose to other extraarticular disease manifestations as well. This was illustrated in a group of rheumatoid factor-positive patients with erosive disease, almost one-half of whom had two shared epitope-positive alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/41\">",
"     41",
"    </a>",
"    ]. Individuals whose shared epitopes were contained in DR4+ alleles (HLA-DRB1*0401, 0404,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    0408) had the highest risk of extraarticular disease, including rheumatoid vasculitis, rheumatoid lung disease, and Felty&rsquo;s syndrome. Patients heterozygous for two shared epitope-containing alleles, one DR4+ and one DR4-, had disease of intermediate severity, while those with a single shared epitope-positive DR4 allele had less severe disease.",
"   </p>",
"   <p>",
"    Progression of joint damage also appears to be more rapid in those with two DR4+ alleles. This was illustrated in a study of patients with early RA; two-thirds of those who had two DR4+ alleles progressed radiographically, while approximately one-half of those with a single DR4+ allele worsened during three years of observation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other evidence is emerging that certain HLA-DRB1 genotypes are associated with early mortality. For example, data from the Norfolk Arthritis Register (NOAR) suggest that carriage of two copies of shared epitope alleles confers a higher risk of death from cardiovascular disease than carriage of zero or one copy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/43\">",
"     43",
"    </a>",
"    ]. The combination of",
"    <span class=\"nowrap\">",
"     HLA-DRB1*01/*04",
"    </span>",
"    conferred the highest hazard ratios [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear whether the association of HLA with severe disease acts solely via the presence of anticyclic citrullinated",
"    <span class=\"nowrap\">",
"     peptide/protein",
"    </span>",
"    antibodies (ACPA), but it is clear that anticyclic citrullinated peptide antibody status (as a sensitive and specific test for ACPA) is a better predictor of erosions than shared epitope status. (See",
"    <a class=\"local\" href=\"#H24811710\">",
"     'Relationship between HLA-DRB1 and anti-CCP antibody status'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MECHANISTIC IMPLICATIONS OF THE SHARED EPITOPE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Theories which explain how expression of the shared epitope contributes to RA focus on the role of the HLA molecule in binding specific peptides and in presenting them to CD4+ T lymphocytes via recognition by the T-cell receptor. The polymorphic residues in the class II molecule determine which peptides are bound with high affinity. Molecules containing the shared epitope bind a different array of peptides than those not containing it [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In an attempt to explain how the shared epitope functions in its contribution to RA, different models have been advanced:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One model suggests that certain pathogenic peptides can be presented to T cells only by shared epitope-positive alleles.",
"     </li>",
"     <li>",
"      In a second model, this differential peptide binding alters the specific T cells that are positively selected in the thymus, thereby leading to a different T-cell repertoire that could include autoreactive, pathogenic T cells.",
"     </li>",
"     <li>",
"      A third model proposes that the HLA molecule is processed and that the shared epitope itself is the relevant antigen, bound by another HLA molecule.",
"     </li>",
"     <li>",
"      Still another theory suggests direct T-cell recognition of the shared epitope, which is more dominant than recognition of the specific peptide bound by the DR molecule.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The concept of molecular mimicry may play a role in several of these models. In this scenario, homology between specific polymorphic residues of the HLA molecule itself and amino acid sequences of potentially antigenic proteins derived from infectious agents could lead to abnormal recognition of a self peptide. One example is the sequence identity noted between the shared epitope and a portion of an Epstein-Barr virus glycoprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/46\">",
"     46",
"    </a>",
"    ]. A slightly different example is the sequence homology between the shared epitope and the DNA heat shock protein (HSP) from Escherichia coli; it has been suggested that mammalian HSP proteins may have a unique avidity for HLA alleles carrying the shared epitope, leading to some aberrant HSP-associated event [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24811710\">",
"    <span class=\"h2\">",
"     Relationship between HLA-DRB1 and anti-CCP antibody status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the identification of anti-citrullinated peptide antibodies (ACPA) and the development of commercial tests based upon recognition by anticyclic citrullinated peptide (anti-CCP) antibodies, there is emerging evidence that anti-CCP positive and anti-CCP negative RA may behave very differently and may actually comprise distinct diseases underpinned by distinct genetic contributions. This is particularly striking for the HLA-DRB1 gene in which, for example, the linkage to the HLA region observed in RA families is absent in anti-CCP negative families [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis\", section on 'Anti-citrullinated peptide antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Subsequent studies have confirmed that there is a significant association between the shared epitope and RA in RA patients who are anti-CCP antibody-positive [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. For example, a significantly greater prevalence of anti-CCP antibodies was found in those who carried two shared epitope alleles than in those with one or no allele (85, 58, and 30 percent, respectively). Hence, the shared epitope seems to predispose to anti-CCP positive RA, and the development of ACPA may be a path variable to explain the association of the shared epitope with RA susceptibility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severity.",
"   </p>",
"   <p>",
"    DR alleles other than the shared epitope (SE) can affect the influence of the SE and other DR alleles on the risk of developing RA. This was shown in a study of 1352 Swedish patients and 922 controls that compared the effects of the SE, DRB1*13, and DRB1*03 on the risk for ACPA-positive and ACPA-negative RA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/52\">",
"     52",
"    </a>",
"    ]. The DRB1*13 allele protected against ACPA-positive RA but, in combination with DRB1*03, increased the risk of ACPA-negative RA.",
"   </p>",
"   <p>",
"    A gene environment interaction between smoking and shared epitope carriage in ACPA-positive RA has been reported in two European populations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/53,54\">",
"     53,54",
"    </a>",
"    ] but has not been replicated in three populations from the US [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/55\">",
"     55",
"    </a>",
"    ]. Smoking has also been reported to be associated with the production of ACPA in shared epitope-negative individuals, so the relationship appears complex [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Citrullination is a process by which positively charged arginine residues are converted to uncharged citrulline. Modeling studies have shown that the shared epitope p4 pocket of the HLA-DRB1 gene should bind citrulline more effectively than arginine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/57\">",
"     57",
"    </a>",
"    ]. Studies in mice carrying the HLA-DRB1*0401 transgene have demonstrated that converting a residue from arginine to citrulline leads to enhanced T-cell activation and increased binding of peptides by the shared epitope [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/57\">",
"     57",
"    </a>",
"    ]. Hence, it has been speculated that smoking leads to increased citrullination of proteins. Carriage of shared epitope alleles in this environmental background increases susceptibility to RA because they bind citrullinated peptides more strongly and induce an exaggerated T-cell response. The exaggerated T-cell response, in turn, may drive the increased autoantibody production by B cells, including anti-CCP antibodies, seen in RA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/58,59\">",
"     58,59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     RA SUSCEPTIBILITY GENES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although a role for HLA-DR genes in conferring susceptibility to RA is well-accepted, most investigators estimate that HLA contributes to less that 50 percent of the overall genetic risk. The availability of increasingly powerful molecular genetic techniques has ignited the search for other relevant genes in RA. This has generally taken two approaches: investigating candidate genes whose function suggests a possible role in disease pathogenesis, and screening the entire human genome using genome-wide association studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12975424\">",
"    <span class=\"h2\">",
"     Candidate genes within the MHC region",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major histocompatibility complex (MHC) region on chromosome six contains over 200 genes of immunological relevance. Several studies suggest that loci other than HLA-DRB1 may also contribute to susceptibility to RA, but these studies are challenging due to the strong effects of the HLA-DRB1 alleles and to the high degree of linkage disequilibrium across the MHC region. For example, early reports of an association of RA with other classical HLA genes, such as alleles of HLA-DQA1, and with other non-HLA genes such as TNF are likely to be secondary to linkage with the shared epitope-carrying DR genes.",
"   </p>",
"   <p>",
"    After controlling for HLA-DRB1 associations, independent associations are observed at HLA-DPB1, corresponding to amino acid position nine of that molecule, and also to HLA-B, corresponding to HLA-B*08 and equivalently to position nine of that molecule [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/28\">",
"     28",
"    </a>",
"    ]. Both amino acid sites sit at the base of the binding groove of those proteins.",
"   </p>",
"   <p>",
"    Non-HLA genes within the MHC have also been investigated for association with RA. The genes for tumor necrosis factor (TNF) lie within the MHC and have been a focus of intense interest, given the demonstration that TNF-alpha plays a central role in the inflammatory cascade in affected joints and given the striking efficacy of TNF-alpha antagonists as therapeutic agents. Results of such investigations, however, have been conflicting; some studies report an association of particular TNF markers with RA [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/60-64\">",
"     60-64",
"    </a>",
"    ], while others find no differences [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/65-69\">",
"     65-69",
"    </a>",
"    ]. However, it is likely that HLA-DRB1 is not the only RA susceptibility gene in the MHC region. The association with TNF is most likely a function of alleles in linkage with HLA-B*08 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3319549\">",
"    <span class=\"h2\">",
"     Candidate genes outside the MHC region",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of genes outside of the MHC also exhibit an association with RA, and some are associated with other autoimmune conditions as well. A large number of confirmed associations with RA susceptibility have been reported. Since 2007, there has been an explosion in the number of RA susceptibility genes identified and confirmed in well-powered cohorts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. For most of the reported associations (with the exception of the R620W PTPN22 allele), the actual causal variant has not been identified, and the gene thought to be responsible for the association may change as fine-mapping studies are undertaken. Most associated variants are intragenic or intronic variants that do not confer a change in the amino acid sequence of gene protein products. These studies are underway, so a better understanding of which genes are involved, of whether the same variants are associated with multiple autoimmune diseases, and of whether multiple variants at a locus contribute to susceptibility should become clearer as research progresses.",
"   </p>",
"   <p>",
"    The PADI4 gene appears to be a real RA disease gene in the Japanese but not in populations of northern European descent. Conversely, the R620W PTPN22 polymorphism has been consistently associated with RA in populations of northern European descent, but the variant does not exist in the Japanese or Korean populations. STAT4, on the other hand, has been associated with RA in both Caucasian and Asian populations. The identification of susceptibility loci for RA is a rapidly moving field, and there is an ever expanding list of confirmed hits.",
"   </p>",
"   <p>",
"    Genetic loci with confirmed evidence for association in multiple populations include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PTPN22 gene &mdash; The protein tyrosine phosphatase N22 (PTPN22) gene helps regulate both T and B cells. The frequency of a single nucleotide polymorphism (SNP) in the gene was increased in patients versus healthy controls in studies of multiple North American and European Caucasian populations but not in Koreans [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/70\">",
"       70",
"      </a>",
"      ]. The SNP encodes an amino acid substitution at position 620 (R620W), which affects binding to an intracellular signaling molecule called Csk [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/74\">",
"       74",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The polymorphism is also associated with type 1 diabetes, juvenile idiopathic arthritis, Hashimoto&rsquo;s thyroiditis, and Addison&rsquo;s disease but not with multiple sclerosis, psoriatic arthritis, or psoriasis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/75\">",
"       75",
"      </a>",
"      ]. An association with systemic lupus erythematosus has also been noted [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/76\">",
"       76",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In mice, the corresponding gene is a negative regulator of T cells [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/74\">",
"       74",
"      </a>",
"      ]. The W620 variant of PTPN22*R620W binds Csk less efficiently than the R620 allele, which may predispose to autoimmunity by resulting in a failure to switch off T cells. In other experiments, however, the polymorphism has been shown to be a &ldquo;gain of function&rdquo; variant (ie, it increases the down-regulation of T cells). This is postulated to predispose to autoimmunity by failure to delete autoreactive T cells during thymic development [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/77\">",
"       77",
"      </a>",
"      ]. A study has also demonstrated that levels of the 620W PTPN22 variant are decreased in human T and B cells, and its calpain binding and cleavage were increased relative to wild-type Lyp620R. Based upon mouse experiments, this difference was attributed to calpain-mediated degradation. This consequently reduced expression and also reduced lymphocyte and dendritic cell hyperresponsiveness [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/78\">",
"       78",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      STAT4 gene &mdash; STAT4 encodes a transcription factor that transmits signals induced by several key cytokines, including interleukin (IL)-12 and type 1 interferons, as well as IL-23 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/79\">",
"       79",
"      </a>",
"      ]. STAT4-dependent signaling by IL-12 receptors plays a critical role in the development of Th1-type responses. A variant allele of STAT4 confers an increased risk of both RA and systemic lupus erythematosus (SLE) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/80\">",
"       80",
"      </a>",
"      ]. Homozygosity of the risk allele is associated with a more than doubled risk of SLE and with a 60 percent increased risk of RA.",
"     </li>",
"     <li>",
"      TRAF1-C5 gene locus &mdash; The TRAF1 gene encodes TNF receptor-associated factor 1, and the C5 gene encodes complement component five. A genome-wide analysis of North American and Swedish patients revealed that a common genetic variant at the TRAF1-C5 locus on chromosome nine, identified by the rs3761847 SNP, appeared to increase the risk of anti-CCP antibody-positive RA [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/81\">",
"       81",
"      </a>",
"      ]. This association, however, was not seen in a cohort of Korean patients with RA [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/82\">",
"       82",
"      </a>",
"      ]. By contrast, the rs7021206 SNP of the TRAF1 gene was associated with RA in both Caucasian and Korean populations [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chromosome 6q23 &mdash; An intergenic region between the OLIG3 and TNFAIP3 genes on chromosome 6q23 has been associated with RA susceptibility in both US and UK populations [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/84,85\">",
"       84,85",
"      </a>",
"      ]. The association in the region is complex with at least three variants independently contributing to overall susceptibility [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/86\">",
"       86",
"      </a>",
"      ]. It is thought that the variants may be affecting the function",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      regulation of the TNFAIP3 gene as knock-out mice develop severe inflammation, which includes inflammation of joints [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/87\">",
"       87",
"      </a>",
"      ]. However, although the intergenic region is certainly associated with RA susceptibility, the involvement of the TNFAIP3 gene has not been confirmed.",
"     </li>",
"     <li>",
"      PADI-4 gene &mdash; Genes for enzymes that are responsible for post-translational modification of peptidylarginine to peptidylcitrulline, an antigenic side chain against which autoantibodies are found in many patients with RA, may contribute to the risk of developing disease. Of the four isotypes of PADI, types 2 and 4 are considered to be the most likely to be present in human synovium in which citrullination of matrix proteins could potentially create antigenic peptides [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/88-90\">",
"       88-90",
"      </a>",
"      ]. Furthermore, levels of PAD-2 and PAD-4 were correlated with the level of inflammation in RA synovium [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/90\">",
"       90",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In two case-control studies, significant association was noted between different haplotypes coding for one of four such enzymes (peptidylarginine deiminase 4 or PADI4) and the presence or absence of RA in a Japanese population [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/91,92\">",
"       91,92",
"      </a>",
"      ]. Association has also been detected in Korean populations and North American populations [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/93,94\">",
"       93,94",
"      </a>",
"      ] but not in patients from Europe [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/95-98\">",
"       95-98",
"      </a>",
"      ]. Further study of this association in additional populations is needed.",
"     </li>",
"     <li>",
"      CTLA-4 gene &mdash; A meta-analysis and separate well-powered validation studies have confirmed association of RA with variants within the CTLA-4 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/99,100\">",
"       99,100",
"      </a>",
"      ]. Previous work has shown that the associated variant (rs3087243) maps within the 3' region of the CTLA-4 gene and is correlated with the ratio of soluble to full-length CTLA4 mRNA levels [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/101\">",
"       101",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      IL-2 and IL-21 gene region &mdash; The IL-2 and IL-21 locus on chromosome 4q27 is associated with type 1 diabetes, celiac disease, and RA in several large series [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/99,100,102\">",
"       99,100,102",
"      </a>",
"      ]. The region exhibits substantial linkage disequilibrium encompassing both the IL-2 and IL-21 genes. Since both are good candidates as autoimmunity susceptibility genes, it will be challenging to identify the responsible polymorphism.",
"     </li>",
"     <li>",
"      PRKCQ gene &mdash; RA is associated with a variant that maps to chromosome 10p15 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/99,103\">",
"       99,103",
"      </a>",
"      ]. The closest gene is the PRKCQ gene, which encodes a kinase required for the activation of the transcription factors NF-kappaB and AP-1; it is thought to play a key role in T cell activation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/104\">",
"       104",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      KIF5A gene &mdash; A SNP mapping to intron 15 of the KIF5A gene has also been associated with RA susceptibility [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/99,103\">",
"       99,103",
"      </a>",
"      ]. The gene encodes a kinesin-heavy chain, with mutations being associated with hereditary spastic paraplegia. Thus, it is not an obvious candidate RA susceptibility gene, and further work to determine whether the SNP is involved in the regulation of KIF5A itself or another gene in the region is required.",
"     </li>",
"     <li>",
"      IL-2RB gene &mdash; A SNP in the promoter region of the gene for the beta unit of the IL-2 receptor (IL-2RB) has shown strong evidence for association with RA [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/103\">",
"       103",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      AFF3 gene &mdash; Modest evidence for association of the AFF3 gene with susceptibility to RA has been reported in a genome-wide study and in two independent validation cohorts [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/100,103\">",
"       100,103",
"      </a>",
"      ]. This gene is preferentially expressed in lymphoid cells and encodes a nuclear factor that can interact with DNA and that contains transcriptional activation domains. The combined evidence for the association was strong across all three cohorts.",
"     </li>",
"     <li>",
"      CD40 gene &mdash; A meta-analysis of available data from genome-wide association studies of RA showed strong evidence for association of the CD40 gene with RA susceptibility [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/99\">",
"       99",
"      </a>",
"      ]. CD40, which is expressed on B cells, monocytes, and dendritic cells, interacts with CD154 on T cells. This interaction is important in immunoglobulin class switching, in memory B-cell development, and in germinal center formation.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       CD2/CD58",
"      </span>",
"      gene region &mdash; Confirmed evidence for association with a SNP at this locus was obtained from an international meta-analysis of RA samples [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/105\">",
"       105",
"      </a>",
"      ]. CD2 is a costimulatory molecule which is found on natural killer and T cells, whilst CD58 interacts with CD2 to stimulate T-cell adhesion and activation.",
"     </li>",
"     <li>",
"      CD28 gene &mdash; A meta-analysis of approximately 3400 RA cases and 12,500 controls with replication in an independent set of approximately 8000 independent RA cases and 12,000 independent controls confirmed association with a variant lying close to the CD28 gene at genome-wide significant levels [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/105\">",
"       105",
"      </a>",
"      ]. This gene lies on chromosome 2q, and association of CTLA-4 and STAT4 with RA, both of which map close by, has already been described above. Hence, this seems to be a region harboring multiple RA susceptibility genes. The CD28 gene encodes a costimulatory molecule required for T-cell proliferation and survival.",
"     </li>",
"     <li>",
"      PRDM1 gene region &mdash; The same international meta-analysis also found association to the PRDM1 gene region [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/105\">",
"       105",
"      </a>",
"      ]. This gene product is a transcription factor involved in B cell regulation.",
"     </li>",
"     <li>",
"      SPRED2 gene &mdash; Association at this locus was reported in an expanded meta-analysis of six genome-wide association studies in Caucasian RA samples from the US, UK, Sweden, and Canada, all of whom were anti-CCP antibody-positive [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/106\">",
"       106",
"      </a>",
"      ]. The associated SNP mapped to intron 1 of the gene, which is involved in regulating CD45+ cells via the Ras-MAP kinase pathway.",
"     </li>",
"     <li>",
"      IL-6ST gene region &mdash; In the expanded meta-analysis described above, which included a total of approximately 41,000 samples (12,000 RA cases and 29,000 controls), association at 5q11 was detected [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/106\">",
"       106",
"      </a>",
"      ]. The most associated variant was actually found in an adjacent gene, ANKRD55, but IL-6 signal transducer (IL-6ST) was felt to be a better candidate based upon its immunological function, which involves the IL-6 signaling pathway.",
"     </li>",
"     <li>",
"      5q21 gene region &mdash; Genome-wide evidence for association to the 5q21 region was reported in the expanded meta-analysis, but, interestingly, the region contains no obvious candidate genes [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      PXK &mdash; A SNP mapping within the PXK gene has been reported previously to be associated with SLE. However, a different variant close to but not within the gene was more strongly associated with RA in the expanded meta-analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      RBPJ &mdash; A RBPJ SNP has been associated with type 1 diabetes and was strongly associated with RA in the expanded meta-analysis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/106\">",
"       106",
"      </a>",
"      ]. The gene encodes a transcription factor involved in the notch signaling pathway and implicated in regulating T-cell development.",
"     </li>",
"     <li>",
"      CCR6 &mdash; The CCR6 gene is a cell surface receptor which is involved in recognizing Th17 cells. SNPs mapping to the gene region have been associated with both Crohn&rsquo;s disease and RA [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/106\">",
"       106",
"      </a>",
"      ]. However, different SNPs are associated with each disease.",
"     </li>",
"     <li>",
"      IRF5 &mdash; Two independent association signals were detected at the IRF5 locus with RA [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/106\">",
"       106",
"      </a>",
"      ]. The IRF5 gene has been widely confirmed as being associated with SLE. IRF5 belongs to a family of transcription factors involved in antiviral and antiinflammatory responses, but experimental evidence suggests that it may also regulate differentiation of B cells.",
"     </li>",
"     <li>",
"      CCL21 &mdash; Two independent effects at CCL21 have also been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/99,106\">",
"       99,106",
"      </a>",
"      ]. The gene product is a chemokine that attracts activated T cells but that does not attract B cells, macrophages, or neutrophils.",
"     </li>",
"     <li>",
"      IL-2RA &mdash; IL-2RA has been associated with multiple autoimmune diseases including type 1 diabetes, juvenile idiopathic arthritis, and multiple sclerosis. The expanded meta-analysis confirmed association of RA with this locus, but the pattern of association in the region is complex with different SNPs and haplotypes associated with the different autoimmune diseases [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/106\">",
"       106",
"      </a>",
"      ]. IL-2RA protein mediates IL-2 dependent T-cell responses.",
"     </li>",
"     <li>",
"      REL &mdash; Association of the REL locus, which encodes a gene involved in NFkB signaling, was detected in an expanded genome-wide association study of US subjects with replication in US and Canadian samples [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/107\">",
"       107",
"      </a>",
"      ]. Association has subsequently been independently replicated in UK samples [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     RA SEVERITY GENES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     HLA genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies support an association of shared epitope with erosive disease. In 2004, a meta-analysis of the impact of shared epitope positive alleles on erosive disease summarized the results of 10 studies (1027 patients) and found that carriage of one or two such alleles was associated with an odds ratio of having joint erosion of about 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/39\">",
"     39",
"    </a>",
"    ]. The retrospective association of specific HLA alleles with severe RA raised the question of whether typing may be useful to predict which patients will progress to destructive disease, as HLA markers, unlike levels of rheumatoid factor (RF) or acute phase reactants, are stable over time and are not subject to fluctuation with disease course or treatment.",
"   </p>",
"   <p>",
"    Verification of the predictive value of HLA markers is, therefore, an important issue that has been evaluated in a number of prospective studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/10,109\">",
"     10,109",
"    </a>",
"    ]. The majority supports an association of shared epitope alleles with severe disease, most often assessed by the presence of erosions. This association between DR4+ susceptibility alleles and erosive disease is confirmed among non-Caucasian patients, including Koreans [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/37\">",
"     37",
"    </a>",
"    ] and Japanese [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/38\">",
"     38",
"    </a>",
"    ]. However, HLA shared epitope is also associated with the presence of anti-CCP antibodies. These are more predictive of severe disease and are easier to measure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cardiovascular disease is a common comorbidity in RA and is associated with reduced life expectancy in patients with RA. Several studies have shown that carrying two copies of shared epitope alleles is associated with premature mortality and with cardiovascular mortality, and this effect appears independent of anti-CCP status [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/43,111-114\">",
"     43,111-114",
"    </a>",
"    ]. Indeed, one study reported that patients with inflammatory polyarthritis who were smokers, who were anti-CCP positive, and who carried two copies of shared epitope alleles had a 7.8-fold increased risk of premature mortality from cardiovascular disease compared with patients without the risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Non-HLA genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other non-HLA genes or genetic loci have been investigated in terms of whether they can predict severity. The following are likely associated with severity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RA patients with the FCGR2B 695T&gt;C allele were much more likely to develop joint damage [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/115\">",
"       115",
"      </a>",
"      ]. This allele radically alters dendritic cell behavior, suggesting a key role for dendritic cells in RA pathology.",
"     </li>",
"     <li>",
"      Variants within the 6q23 intergenic region are associated with the rate of joint destruction in RA patients who are anti-CCP positive [",
"      <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/116\">",
"       116",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other investigated genes, including TNF, MBL, CCR5 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/117\">",
"     117",
"    </a>",
"    ], and PADI4 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/118\">",
"     118",
"    </a>",
"    ] genes, have not been convincingly shown to be associated with RA severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     GENES DETERMINING RESPONSE TO TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that knowledge of a patient&rsquo;s HLA status may be useful in predicting the response to specific therapies. This issue was addressed in a study in which 84 Caucasian patients with RA, who had participated in a trial comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) alone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (HCQ) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ), and triple therapy with all three drugs, were genotyped for the presence and number of shared epitope (SE) alleles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/119\">",
"     119",
"    </a>",
"    ]. A marked difference in treatment response was observed in patients when stratified by shared epitope status:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among shared epitope positive patients, those who received triple therapy were significantly more likely than those receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      alone to meet the criteria for a successful clinical response (94 versus 32 percent). Those in the HCQ plus SSZ group had intermediate outcomes. In the MTX-only group, there was a correlation of response with gene dose.",
"     </li>",
"     <li>",
"      Response rates were higher in those without the SE compared with those with a single dose or a double dose (83, 36, and 25 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results suggest that patients with one or, especially, two doses of the shared epitope may benefit from earlier, more aggressive treatment to control disease. Genetic information is likely to influence clinical decision-making in the future. However, limited numbers of patients have been studied, and further evidence is required [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/120\">",
"     120",
"    </a>",
"    ]. Thus, additional prospective and longer-term studies are needed to better assess the role of testing for the SE in choosing treatment for patients with RA. Such testing is only appropriately performed as a research tool.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CLINICAL USE OF GENETIC MARKERS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     For diagnosis or screening of RA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic markers are not useful for diagnosis or screening of RA. Although certain HLA alleles are strongly associated with severe RA, these alleles are common in the normal population. The absolute risk of developing RA among Caucasians carrying the DR alleles 0401, 0404, or 0101 is approximately 1 in 46 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/121\">",
"     121",
"    </a>",
"    ]. The highest calculated absolute risk is present in individuals expressing both HLA-DRB1*0401 and 0404, but this is still only about one in seven. Even knowing the genotype at the second confirmed RA susceptibility locus, the PTPN22 gene, the predictive value remains too low to be useful for either diagnosis or population screening. Presence of anti-CCP antibodies does predict the future development of RA, particularly severe RA, and one report suggested that the presence of two copies of the shared epitope with one or two copies of PTPN22 risk alleles increased the risk of developing anti-CCP positive RA by 25-fold [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     For estimating prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine typing for HLA markers and shared epitope status cannot be recommended, given the predictive value of other markers, including anti-CCP antibodies and rheumatoid factor (RF), and given the limited availability and potential cost of the technology required to type for shared epitope (SE) alleles.",
"   </p>",
"   <p>",
"    Once the diagnosis of RA is established, genotyping for SE alleles may help predict which patients are at highest risk of severe and erosive disease, and, thus, which are candidates for early and aggressive intervention. This information may be less important clinically if patients with early RA are aggressively treated with potent DMARD regimens, consistent with recommended approaches to disease management.",
"   </p>",
"   <p>",
"    RF testing and anti-CCP antibody testing are the most useful tests that are widely available in predicting which patients with early inflammatory arthritis will develop erosions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/110\">",
"     110",
"    </a>",
"    ]. The presence of erosions is a predictor of poor prognosis, regardless of HLA type.",
"   </p>",
"   <p>",
"    The presence of HLA SE alleles is strongly correlated with the presence of anti-CCP antibodies. Whether knowledge of SE status provides additional predictive value for the development of erosive disease beyond knowledge of anti-CCP status alone remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/110,123\">",
"     110,123",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is also unclear whether genetic markers can be identified that could predict a subgroup, which would not require such aggressive intervention and could be spared the risk of potential adverse events. Genome-wide association data are being investigated to identify predictors of severity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Role of ethnicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the information and hypotheses regarding clinical utility of genetic testing are based primarily upon data derived from North American and northern European Caucasian patients. HLA typing of patients from other racial groups will have different implications. As an example, the lack of a disease-associated DR4 allele in an African American patient does not necessarily imply that he or she is not at high risk of developing erosive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/63/23546/abstract/124\">",
"     124",
"    </a>",
"    ]. On the other hand, as described above, most populations show a strong association with one or more shared epitope-positive DR alleles; testing methods should be easily adaptable to inclusion of those alleles for appropriate ethnic groups in any RA-oriented &ldquo;panel&rdquo; of susceptibility alleles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342906592\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two alleles, DRB1*0401 and DRB1*0404, primarily account for the originally observed serological association of DR4 with rheumatoid arthritis (RA) in Caucasians. The most strongly associated RA alleles share a region of highly similar amino acid sequence, called the shared epitope, located at amino acids 67 to 74, though its functional role in causing disease is unknown. Diverse ethnic populations can display a very different genetic background from Caucasians, but most studies confirm a significant increase in the frequency of alleles containing the shared epitope in RA patients. Additionally, some HLA-DRB1 alleles may protect against the development of RA rather than enhance the risk. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'HLA class II associations in rheumatoid arthritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most studies have found a correlation between DR4+ RA-associated alleles and more severe, erosive disease in both Caucasian and non-Caucasian patients; some studies also note an increase in DR1 among patients with milder disease. The specific combination of shared epitope-positive alleles also appears to be important. The presence of a shared epitope in a DR4+ allele may also predispose to extraarticular disease manifestations, to more rapid progression of joint damage, and to early mortality. Several non-HLA genes or genetic loci also appear to be associated with more severe disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'HLA alleles and severity of RA'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'RA severity genes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Theories to explain how expression of the shared epitope contributes to RA focus on the role of the human leukocyte antigen (HLA) molecule in binding specific peptides and in presenting them to CD4+ T lymphocytes via recognition by the T-cell receptor. The polymorphic residues in the class II molecule determine which peptides are bound with high affinity. Molecules containing the shared epitope bind a different array of peptides than those not containing it. Several different models have been proposed to explain how the shared epitope functions to contribute to RA. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Mechanistic implications of the shared epitope'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evidence suggests that individual amino acid positions in DRB1 and, in particular, position 11 at the base of binding groove may actually explain disease susceptibility better than the shared epitope sequence.",
"     </li>",
"     <li>",
"      There is emerging evidence that anticyclic citrullinated peptide (CCP) positive and anti-CCP negative RA may behave very differently and may comprise distinct diseases underpinned by distinct genetic contributions. The shared epitope seems to predispose to anti-CCP positive RA, and the development of anti-citrullinated peptide antibodies may be a path variable to explain the association of the shared epitope with RA susceptibility",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severity. (See",
"      <a class=\"local\" href=\"#H24811710\">",
"       'Relationship between HLA-DRB1 and anti-CCP antibody status'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HLA may contribute less than 50 percent of the overall genetic risk for RA. Loci within the major histocompatibility complex (MHC) other than HLA-DRB1 may also contribute to susceptibility, and a number of genes outside of the MHC also exhibit an association with RA, some of which are also associated with other autoimmune conditions. Most associated variants outside the MHC are intragenic or intronic variants that do not confer a change in the amino acid sequence of gene protein products. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'RA susceptibility genes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Knowledge of a patient&rsquo;s HLA status and other genetic markers may be useful with further development in diagnosis and screening, in estimating prognosis, and in predicting the response to specific therapies, but a role for HLA testing in RA outside the research setting has not been established. As an example, patients with one or, especially, two doses of the shared epitope may benefit from earlier, more aggressive treatment to control disease. However, most of the information and hypotheses regarding clinical utility of genetic testing are based primarily upon data derived from North American and northern European Caucasian patients, and HLA typing of patients from other racial groups will have different implications. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Genes determining response to treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Clinical use of genetic markers'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/1\">",
"      McMichael AJ, Sasazuki T, McDevitt HO, Payne RO. Increased frequency of HLA-Cw3 and HLA-Dw4 in rheumatoid arthritis. Arthritis Rheum 1977; 20:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/2\">",
"      Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978; 298:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/3\">",
"      Nepom BS, Nepom GT. Polyglot and polymorphism. An HLA update. Arthritis Rheum 1995; 38:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/4\">",
"      Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/5\">",
"      Willkens RF, Nepom GT, Marks CR, et al. Association of HLA-Dw16 with rheumatoid arthritis in Yakima Indians. Further evidence for the \"shared epitope\" hypothesis. Arthritis Rheum 1991; 34:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/6\">",
"      van der Woude D, Houwing-Duistermaat JJ, Toes RE, et al. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum 2009; 60:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/7\">",
"      Nepom GT, Byers P, Seyfried C, et al. HLA genes associated with rheumatoid arthritis. Identification of susceptibility alleles using specific oligonucleotide probes. Arthritis Rheum 1989; 32:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/8\">",
"      Wordsworth BP, Lanchbury JS, Sakkas LI, et al. HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci U S A 1989; 86:10049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/9\">",
"      R&oslash;nningen KS, Spurkland A, Egeland T, et al. Rheumatoid arthritis may be primarily associated with HLA-DR4 molecules sharing a particular sequence at residues 67-74. Tissue Antigens 1990; 36:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/10\">",
"      Fries JF, Wolfe F, Apple R, et al. HLA-DRB1 genotype associations in 793 white patients from a rheumatoid arthritis inception cohort: frequency, severity, and treatment bias. Arthritis Rheum 2002; 46:2320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/11\">",
"      Yamada R, Yamamoto K. Mechanisms of disease: genetics of rheumatoid arthritis--ethnic differences in disease-associated genes. Nat Clin Pract Rheumatol 2007; 3:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/12\">",
"      Ohta N, Nishimura YK, Tanimoto K, et al. Association between HLA and Japanese patients with rheumatoid arthritis. Hum Immunol 1982; 5:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/13\">",
"      Molkentin J, Gregersen PK, Lin X, et al. Molecular analysis of HLA-DR beta and DQ beta polymorphism in Chinese with rheumatoid arthritis. Ann Rheum Dis 1993; 52:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/14\">",
"      Nelson JL, Boyer G, Templin D, et al. HLA antigens in Tlingit Indians with rheumatoid arthritis. Tissue Antigens 1992; 40:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/15\">",
"      Williams RC, Jacobsson LT, Knowler WC, et al. Meta-analysis reveals association between most common class II haplotype in full-heritage Native Americans and rheumatoid arthritis. Hum Immunol 1995; 42:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/16\">",
"      Harvey J, Lotze M, Arnett FC, et al. Rheumatoid arthritis in a Chippewa band. II. Field study with clinical serologic and HLA-D correlations. J Rheumatol 1983; 10:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/17\">",
"      Yelamos J, Garcia-Lozano JR, Moreno I, et al. Association of HLA-DR4-Dw15 (DRB1*0405) and DR10 with rheumatoid arthritis in a Spanish population. Arthritis Rheum 1993; 36:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/18\">",
"      de Juan MD, Belmonte I, Barado J, et al. Differential associations of HLA-DR antigens with rheumatoid arthritis (RA) in Basques: high frequency of DR1 and DR10 and lack of association with HLA-DR4 or any of its subtypes. Tissue Antigens 1994; 43:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/19\">",
"      Schiff B, Mizrachi Y, Orgad S, et al. Association of HLA-Aw31 and HLA-DR1 with adult rheumatoid arthritis. Ann Rheum Dis 1982; 41:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/20\">",
"      de Vries N, R&oslash;nningen KS, Tilanus MG, et al. HLA-DR1 and rheumatoid arthritis in Israeli Jews: sequencing reveals that DRB1*0102 is the predominant HLA-DR1 subtype. Tissue Antigens 1993; 41:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/21\">",
"      Hughes LB, Morrison D, Kelley JM, et al. The HLA-DRB1 shared epitope is associated with susceptibility to rheumatoid arthritis in African Americans through European genetic admixture. Arthritis Rheum 2008; 58:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/22\">",
"      Boki KA, Panayi GS, Vaughan RW, et al. HLA class II sequence polymorphisms and susceptibility to rheumatoid arthritis in Greeks. The HLA-DR beta shared-epitope hypothesis accounts for the disease in only a minority of Greek patients. Arthritis Rheum 1992; 35:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/23\">",
"      van der Helm-van Mil AH, Huizinga TW, Schreuder GM, et al. An independent role of protective HLA class II alleles in rheumatoid arthritis severity and susceptibility. Arthritis Rheum 2005; 52:2637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/24\">",
"      Mattey DL, Dawes PT, Gonzalez-Gay MA, et al. HLA-DRB1 alleles encoding an aspartic acid at position 70 protect against development of rheumatoid arthritis. J Rheumatol 2001; 28:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/25\">",
"      Reviron D, Perdriger A, Toussirot E, et al. Influence of shared epitope-negative HLA-DRB1 alleles on genetic susceptibility to rheumatoid arthritis. Arthritis Rheum 2001; 44:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/26\">",
"      de Vries N, Tijssen H, van Riel PL, van de Putte LB. Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67-74 of the HLA-DRB1 molecule. Arthritis Rheum 2002; 46:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/27\">",
"      Feitsma AL, Worthington J, van der Helm-van Mil AH, et al. Protective effect of noninherited maternal HLA-DR antigens on rheumatoid arthritis development. Proc Natl Acad Sci U S A 2007; 104:19966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/28\">",
"      Raychaudhuri S, Sandor C, Stahl EA, et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat Genet 2012; 44:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/29\">",
"      Young A, Jaraquemada D, Awad J, et al. Association of HLA-DR4/Dw4 and DR2/Dw2 with radiologic changes in a prospective study of patients with rheumatoid arthritis. Preferential relationship with HLA-Dw rather than HLA-DR specificities. Arthritis Rheum 1984; 27:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/30\">",
"      Calin A, Elswood J, Klouda PT. Destructive arthritis, rheumatoid factor, and HLA-DR4. Susceptibility versus severity, a case-control study. Arthritis Rheum 1989; 32:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/31\">",
"      van Zeben D, Hazes JM, Zwinderman AH, et al. Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study. Arthritis Rheum 1991; 34:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/32\">",
"      Eberhardt K, Fex E, Johnson U, Wollheim FA. Associations of HLA-DRB and -DQB genes with two and five year outcome in rheumatoid arthritis. Ann Rheum Dis 1996; 55:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/33\">",
"      Valenzuela-Casta&ntilde;o A, Garc&iacute;a-L&oacute;pez A, P&eacute;rez-Vilches D, et al. The predictive value of the HLA shared epitope for severity of radiological joint damage in patients with rheumatoid arthritis. A 10 year observational prospective study. J Rheumatol 2000; 27:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/34\">",
"      Rau R, Herborn G, Zueger S, Fenner H. The effect of HLA-DRB1 genes, rheumatoid factor, and treatment on radiographic disease progression in rheumatoid arthritis over 6 years. J Rheumatol 2000; 27:2566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/35\">",
"      Olsen NJ, Callahan LF, Brooks RH, et al. Associations of HLA-DR4 with rheumatoid factor and radiographic severity in rheumatoid arthritis. Am J Med 1988; 84:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/36\">",
"      McMahon MJ, Hillarby MC, Clarkson RW, et al. Major histocompatibility complex variants and articular disease severity in rheumatoid arthritis. Br J Rheumatol 1993; 32:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/37\">",
"      Kim HY, Min JK, Yang HI, et al. The impact of HLA-DRB1*0405 on disease severity in Korean patients with seropositive rheumatoid arthritis. Br J Rheumatol 1997; 36:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/38\">",
"      Wakitani S, Murata N, Toda Y, et al. The relationship between HLA-DRB1 alleles and disease subsets of rheumatoid arthritis in Japanese. Br J Rheumatol 1997; 36:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/39\">",
"      Gorman JD, Lum RF, Chen JJ, et al. Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients. Arthritis Rheum 2004; 50:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/40\">",
"      Wordsworth P, Pile KD, Buckely JD, et al. HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. Am J Hum Genet 1992; 51:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/41\">",
"      Weyand CM, Hicok KC, Conn DL, Goronzy JJ. The influence of HLA-DRB1 genes on disease severity in rheumatoid arthritis. Ann Intern Med 1992; 117:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/42\">",
"      Combe B, Dougados M, Goupille P, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum 2001; 44:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/43\">",
"      Farragher TM, Goodson NJ, Naseem H, et al. Association of the HLA-DRB1 gene with premature death, particularly from cardiovascular disease, in patients with rheumatoid arthritis and inflammatory polyarthritis. Arthritis Rheum 2008; 58:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/44\">",
"      Fu XT, Bono CP, Woulfe SL, et al. Pocket 4 of the HLA-DR(alpha,beta 1*0401) molecule is a major determinant of T cells recognition of peptide. J Exp Med 1995; 181:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/45\">",
"      Kirschmann DA, Duffin KL, Smith CE, et al. Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles. J Immunol 1995; 155:5655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/46\">",
"      Roudier J, Rhodes G, Petersen J, et al. The Epstein-Barr virus glycoprotein gp110, a molecular link between HLA DR4, HLA DR1, and rheumatoid arthritis. Scand J Immunol 1988; 27:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/47\">",
"      Auger I, Escola JM, Gorvel JP, Roudier J. HLA-DR4 and HLA-DR10 motifs that carry susceptibility to rheumatoid arthritis bind 70-kD heat shock proteins. Nat Med 1996; 2:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/48\">",
"      Huizinga TW, Amos CI, van der Helm-van Mil AH, et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum 2005; 52:3433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/49\">",
"      Irigoyen P, Lee AT, Wener MH, et al. Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles. Arthritis Rheum 2005; 52:3813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/50\">",
"      Michou L, Teixeira VH, Pierlot C, et al. Associations between genetic factors, tobacco smoking and autoantibodies in familial and sporadic rheumatoid arthritis. Ann Rheum Dis 2008; 67:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/51\">",
"      Ding B, Padyukov L, Lundstr&ouml;m E, et al. Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum 2009; 60:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/52\">",
"      Lundstr&ouml;m E, K&auml;llberg H, Smolnikova M, et al. Opposing effects of HLA-DRB1*13 alleles on the risk of developing anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum 2009; 60:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/53\">",
"      Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006; 54:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/54\">",
"      van der Helm-van Mil AH, Verpoort KN, le Cessie S, et al. The HLA-DRB1 shared epitope alleles differ in the interaction with smoking and predisposition to antibodies to cyclic citrullinated peptide. Arthritis Rheum 2007; 56:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/55\">",
"      Lee HS, Irigoyen P, Kern M, et al. Interaction between smoking, the shared epitope, and anti-cyclic citrullinated peptide: a mixed picture in three large North American rheumatoid arthritis cohorts. Arthritis Rheum 2007; 56:1745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/56\">",
"      Verpoort KN, Papendrecht-van der Voort EA, van der Helm-van Mil AH, et al. Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles. Arthritis Rheum 2007; 56:2913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/57\">",
"      Hill JA, Southwood S, Sette A, et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003; 171:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/58\">",
"      Auger I, Sebbag M, Vincent C, et al. Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen. Arthritis Rheum 2005; 52:3424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/59\">",
"      van der Helm-van Mil AH, Verpoort KN, Breedveld FC, et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum 2006; 54:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/60\">",
"      Danis VA, Millington M, Hyland V, et al. Increased frequency of the uncommon allele of a tumour necrosis factor alpha gene polymorphism in rheumatoid arthritis and systemic lupus erythematosus. Dis Markers 1995; 12:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/61\">",
"      Mulcahy B, Waldron-Lynch F, McDermott MF, et al. Genetic variability in the tumor necrosis factor-lymphotoxin region influences susceptibility to rheumatoid arthritis. Am J Hum Genet 1996; 59:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/62\">",
"      Tuokko J, Nejentsev S, Luukkainen R, et al. HLA haplotype analysis in Finnish patients with rheumatoid arthritis. Arthritis Rheum 2001; 44:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/63\">",
"      Waldron-Lynch F, Adams C, Amos C, et al. Tumour necrosis factor 5' promoter single nucleotide polymorphisms influence susceptibility to rheumatoid arthritis (RA) in immunogenetically defined multiplex RA families. Genes Immun 2001; 2:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/64\">",
"      van Krugten MV, Huizinga TW, Kaijzel EL, et al. Association of the TNF +489 polymorphism with susceptibility and radiographic damage in rheumatoid arthritis. Genes Immun 1999; 1:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/65\">",
"      Wilson AG, de Vries N, van de Putte LB, Duff GW. A tumour necrosis factor alpha polymorphism is not associated with rheumatoid arthritis. Ann Rheum Dis 1995; 54:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/66\">",
"      Low AS, Gonzalez-Gay MA, Akil M, et al. TNF +489 polymorphism does not contribute to susceptibility to rheumatoid arthritis. Clin Exp Rheumatol 2002; 20:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/67\">",
"      Yen JH, Chen CJ, Tsai WC, et al. Tumor necrosis factor promoter polymorphisms in patients with rheumatoid arthritis in Taiwan. J Rheumatol 2001; 28:1788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/68\">",
"      Vinasco J, Bera&uacute;n Y, Nieto A, et al. Polymorphism at the TNF loci in rheumatoid arthritis. Tissue Antigens 1997; 49:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/69\">",
"      Field M, Gallagher G, Eskdale J, et al. Tumor necrosis factor locus polymorphisms in rheumatoid arthritis. Tissue Antigens 1997; 50:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/70\">",
"      Kochi Y, Suzuki A, Yamada R, Yamamoto K. Genetics of rheumatoid arthritis: underlying evidence of ethnic differences. J Autoimmun 2009; 32:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/71\">",
"      Bowes J, Barton A. Recent advances in the genetics of RA susceptibility. Rheumatology (Oxford) 2008; 47:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/72\">",
"      Coenen MJ, Gregersen PK. Rheumatoid arthritis: a view of the current genetic landscape. Genes Immun 2009; 10:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/73\">",
"      Plant D, Flynn E, Mbarek H, et al. Investigation of potential non-HLA rheumatoid arthritis susceptibility loci in a European cohort increases the evidence for nine markers. Ann Rheum Dis 2010; 69:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/74\">",
"      Begovich AB, Carlton VE, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 75:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/75\">",
"      Vang T, Miletic AV, Bottini N, Mustelin T. Protein tyrosine phosphatase PTPN22 in human autoimmunity. Autoimmunity 2007; 40:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/76\">",
"      Chung SA, Criswell LA. PTPN22: its role in SLE and autoimmunity. Autoimmunity 2007; 40:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/77\">",
"      Vang T, Congia M, Macis MD, et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat Genet 2005; 37:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/78\">",
"      Chen R, Stahl EA, Kurreeman FA, et al. Fine mapping the TAGAP risk locus in rheumatoid arthritis. Genes Immun 2011; 12:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/79\">",
"      Watford WT, Hissong BD, Bream JH, et al. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol Rev 2004; 202:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/80\">",
"      Remmers EF, Plenge RM, Lee AT, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007; 357:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/81\">",
"      Plenge RM, Seielstad M, Padyukov L, et al. TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study. N Engl J Med 2007; 357:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/82\">",
"      Lee HS, Korman BD, Le JM, et al. Genetic risk factors for rheumatoid arthritis differ in Caucasian and Korean populations. Arthritis Rheum 2009; 60:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/83\">",
"      Han TU, Bang SY, Kang C, Bae SC. TRAF1 polymorphisms associated with rheumatoid arthritis susceptibility in Asians and in Caucasians. Arthritis Rheum 2009; 60:2577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/84\">",
"      Thomson W, Barton A, Ke X, et al. Rheumatoid arthritis association at 6q23. Nat Genet 2007; 39:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/85\">",
"      Plenge RM, Cotsapas C, Davies L, et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet 2007; 39:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/86\">",
"      Orozco G, Hinks A, Eyre S, et al. Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Hum Mol Genet 2009; 18:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/87\">",
"      Lee EG, Boone DL, Chai S, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000; 289:2350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/88\">",
"      Vossenaar ER, Radstake TR, van der Heijden A, et al. Expression and activity of citrullinating peptidylarginine deiminase enzymes in monocytes and macrophages. Ann Rheum Dis 2004; 63:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/89\">",
"      Chang X, Yamada R, Suzuki A, et al. Localization of peptidylarginine deiminase 4 (PADI4) and citrullinated protein in synovial tissue of rheumatoid arthritis. Rheumatology (Oxford) 2005; 44:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/90\">",
"      Foulquier C, Sebbag M, Clavel C, et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum 2007; 56:3541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/91\">",
"      Suzuki A, Yamada R, Chang X, et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat Genet 2003; 34:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/92\">",
"      Ikari K, Kuwahara M, Nakamura T, et al. Association between PADI4 and rheumatoid arthritis: a replication study. Arthritis Rheum 2005; 52:3054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/93\">",
"      Plenge RM, Padyukov L, Remmers EF, et al. Replication of putative candidate-gene associations with rheumatoid arthritis in &gt;4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am J Hum Genet 2005; 77:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/94\">",
"      Kang CP, Lee HS, Ju H, et al. A functional haplotype of the PADI4 gene associated with increased rheumatoid arthritis susceptibility in Koreans. Arthritis Rheum 2006; 54:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/95\">",
"      Barton A, Bowes J, Eyre S, et al. A functional haplotype of the PADI4 gene associated with rheumatoid arthritis in a Japanese population is not associated in a United Kingdom population. Arthritis Rheum 2004; 50:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/96\">",
"      Harney SM, Meisel C, Sims AM, et al. Genetic and genomic studies of PADI4 in rheumatoid arthritis. Rheumatology (Oxford) 2005; 44:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/97\">",
"      Caponi L, Petit-Teixeira E, Sebbag M, et al. A family based study shows no association between rheumatoid arthritis and the PADI4 gene in a white French population. Ann Rheum Dis 2005; 64:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/98\">",
"      Martinez A, Valdivia A, Pascual-Salcedo D, et al. PADI4 polymorphisms are not associated with rheumatoid arthritis in the Spanish population. Rheumatology (Oxford) 2005; 44:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/99\">",
"      Raychaudhuri S, Remmers EF, Lee AT, et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat Genet 2008; 40:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/100\">",
"      Barton A, Eyre S, Ke X, et al. Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Hum Mol Genet 2009; 18:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/101\">",
"      Ueda H, Howson JM, Esposito L, et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 2003; 423:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/102\">",
"      Zhernakova A, Alizadeh BZ, Bevova M, et al. Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet 2007; 81:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/103\">",
"      Barton A, Thomson W, Ke X, et al. Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. Nat Genet 2008; 40:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/104\">",
"      Hayashi K, Altman A. Protein kinase C theta (PKCtheta): a key player in T cell life and death. Pharmacol Res 2007; 55:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/105\">",
"      Raychaudhuri S, Thomson BP, Remmers EF, et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet 2009; 41:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/106\">",
"      Stahl EA, Raychaudhuri S, Remmers EF, et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet 2010; 42:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/107\">",
"      Gregersen PK, Amos CI, Lee AT, et al. REL, encoding a member of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat Genet 2009; 41:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/108\">",
"      Eyre S, Hinks A, Flynn E, et al. Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population. Ann Rheum Dis 2010; 69:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/109\">",
"      Harrison B, Thomson W, Symmons D, et al. The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis. Arthritis Rheum 1999; 42:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/110\">",
"      Bukhari M, Thomson W, Naseem H, et al. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum 2007; 56:2929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/111\">",
"      Socioeconomic deprivation and rheumatoid disease: what lessons for the health service? ERAS Study Group. Early Rheumatoid Arthritis Study. Ann Rheum Dis 2000; 59:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/112\">",
"      Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al. HLA-DRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med 2003; 114:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/113\">",
"      Gonzalez-Gay MA, Gonzalez-Juanatey C, Lopez-Diaz MJ, et al. HLA-DRB1 and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis. Arthritis Rheum 2007; 57:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/114\">",
"      Mattey DL, Thomson W, Ollier WE, et al. Association of DRB1 shared epitope genotypes with early mortality in rheumatoid arthritis: results of eighteen years of followup from the early rheumatoid arthritis study. Arthritis Rheum 2007; 56:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/115\">",
"      Radstake TR, Petit E, Pierlot C, et al. Role of Fcgamma receptors IIA, IIIA, and IIIB in susceptibility to rheumatoid arthritis. J Rheumatol 2003; 30:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/116\">",
"      Scherer HU, van der Linden MP, Kurreeman FA, et al. Association of the 6q23 region with the rate of joint destruction in rheumatoid arthritis. Ann Rheum Dis 2010; 69:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/117\">",
"      Barton A, John S. Approaches to identifying genetic predictors of clinical outcome in rheumatoid arthritis. Am J Pharmacogenomics 2003; 3:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/118\">",
"      Naseem H, Thomson W, Silman A, et al. The PTPN22*C1858T functional polymorphism is associated with susceptibility to inflammatory polyarthritis but neither this nor other variants spanning the gene is associated with disease outcome. Ann Rheum Dis 2008; 67:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/119\">",
"      O'Dell JR, Nepom BS, Haire C, et al. HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. Ann Rheum Dis 1998; 57:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/120\">",
"      Plenge RM, Criswell LA. Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions. Curr Opin Rheumatol 2008; 20:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/121\">",
"      Nepom GT, Nepom BS. Prediction of susceptibility to rheumatoid arthritis by human leukocyte antigen genotyping. Rheum Dis Clin North Am 1992; 18:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/122\">",
"      Kallberg H, Padyukov L, Plenge RM, et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007; 80:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/123\">",
"      Rojas-Villarraga A, Diaz FJ, Calvo-P&aacute;ramo E, et al. Familial disease, the HLA-DRB1 shared epitope and anti-CCP antibodies influence time at appearance of substantial joint damage in rheumatoid arthritis. J Autoimmun 2009; 32:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/63/23546/abstract/124\">",
"      McDaniel DO, Alarc&oacute;n GS, Pratt PW, Reveille JD. Most African-American patients with rheumatoid arthritis do not have the rheumatoid antigenic determinant (epitope). Ann Intern Med 1995; 123:181.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7487 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23546=[""].join("\n");
var outline_f22_63_23546=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H342906592\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HLA CLASS II ASSOCIATIONS IN RHEUMATOID ARTHRITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Individual alleles and the shared epitope",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Associations in different ethnic populations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3320096\">",
"      Protective HLA alleles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4298962\">",
"      Individual amino acid sites and rheumatoid arthritis risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HLA ALLELES AND SEVERITY OF RA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MECHANISTIC IMPLICATIONS OF THE SHARED EPITOPE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24811710\">",
"      Relationship between HLA-DRB1 and anti-CCP antibody status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      RA SUSCEPTIBILITY GENES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12975424\">",
"      Candidate genes within the MHC region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3319549\">",
"      Candidate genes outside the MHC region",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      RA SEVERITY GENES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HLA genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Non-HLA genes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      GENES DETERMINING RESPONSE TO TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CLINICAL USE OF GENETIC MARKERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      For diagnosis or screening of RA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      For estimating prognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Role of ethnicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H342906592\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/47/33528?source=related_link\">",
"      Clinically useful biologic markers in the diagnosis and assessment of outcome in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39593?source=related_link\">",
"      Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24167?source=related_link\">",
"      Human leukocyte antigens (HLA): A roadmap",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41210?source=related_link\">",
"      Pathogenesis of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_63_23547="Hypoxia altitude test";
var content_f22_63_23547=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54344&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interpreting results of hypoxia altitude simulation testing*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        PaO",
"        <sub>",
"         2",
"        </sub>",
"        (mmHg)",
"       </td>",
"       <td class=\"subtitle1\">",
"        PaO",
"        <sub>",
"         2",
"        </sub>",
"        (kPa)",
"       </td>",
"       <td class=\"subtitle1\">",
"        SpO",
"        <sub>",
"         2",
"        </sub>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;55 mmHg",
"       </td>",
"       <td>",
"        &gt;7.4 kPa",
"       </td>",
"       <td>",
"        &gt;88 percent",
"       </td>",
"       <td>",
"        In-flight oxygen not advised",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50-55 mmHg",
"       </td>",
"       <td>",
"        6.6-7.4 kPa",
"       </td>",
"       <td>",
"        84-88 percent",
"       </td>",
"       <td>",
"        Borderline, a walk test may be helpful",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;50 mmHg",
"       </td>",
"       <td>",
"        &lt;6.6 kPa",
"       </td>",
"       <td>",
"        &lt;84 percent",
"       </td>",
"       <td>",
"        In-flight oxygen advised",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     : arterial partial pressure of oxygen; SpO",
"     <sub>",
"      2",
"     </sub>",
"     : oxygen saturation by pulse oximetry.",
"     <br>",
"      * Hypoxia altitude simulation testing involves breathing a gas mixture of nitrogen with oxygen at 15.1 percent for 20 minutes, as tolerated.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23547=[""].join("\n");
var outline_f22_63_23547=null;
var title_f22_63_23548="Treatment of complicated vaginal candidiasis";
var content_f22_63_23548=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F50932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F50932&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of complicated vaginal candidiasis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Severe vaginitis symptoms&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral fluconazole 150 mg every 72 hours for 2 or 3 doses (depending on severity)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         &nbsp;&nbsp;&nbsp;&nbsp;OR",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Topical antifungal therapy daily for 7 days. A&nbsp;",
"        <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">",
"         low potency topical corticosteroid can be applied to the vulva for 48 hours to relieve symptoms&nbsp;until the antifungal drug&nbsp;exerts its&nbsp;effect.",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Recurrent vulvovaginal candidiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Induction (3 doses of fluconazole 150 mg every 72 hours until asymptomatic) followed by maintenance fluconazole 150 mg once per week for 6 months. If fluconazole is not feasible, options include 10 to 14 days of a topical or oral azole followed by maintenance therapy for 6 months (eg, clotrimazole 200 mg vaginal cream twice weekly or 500 mg vaginal suppository once weekly)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Non-albicans Candida vaginitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Therapy depends upon species identified:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. glabrata: intravaginal boric acid* 600 mg daily for 14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;&nbsp;&nbsp;&nbsp;If failure occurs: 17 percent flucytosine 5 grams nightly for 14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C. krusei: intravaginal clotrimazole, miconazole, or terconazole for 7 to 14 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All other species: Conventional dose fluconazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Compromised&nbsp;host (eg,",
"        <span style=\"font-family: verdana; font-size: 13px;\">",
"         poorly controlled diabetes, immunosuppression, debilitation) and",
"        </span>",
"        Candida isolate susceptible to azoles&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral or topical therapy for 7 to 14 days",
"        <span class=\"subtitle1_single\">",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">",
"         Intravaginal&nbsp;clotrimazole or miconazole for&nbsp;7 days",
"        </span>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Boric acid capsules and flucytosine cream are not commercially available, but can be made by a compounding pharmacy.",
"    </p>",
"    <div class=\"footnotes\">",
"     <p>",
"      &nbsp;* Boric acid capsules can be fatal if swallowed",
"     </p>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23548=[""].join("\n");
var outline_f22_63_23548=null;
var title_f22_63_23549="Fever and rash ddx by sign 2";
var content_f22_63_23549=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54445&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of fever and rash based upon accompanying signs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Mucosal membrane lesions (enanthems)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes simplex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Infectious mononucleosis (palatal petechiae)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Measles (Koplick's spots)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Strawberry tongue",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Atypical measles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Kawasaki disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Scarlet fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Toxic shock syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Varicella zoster",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Ulcerative or vesicular stomatitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hand-foot-mouth disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herpes simplex",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Histoplasmosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory bowel disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Secondary syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Systemic lupus erythematosus",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Palm-sole involvement",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute meningococcemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atypical measles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Dengue",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Drug rash",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythema multiforme",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hand-foot-mouth disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Kawasaki syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Measles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rocky Mountain spotted fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Secondary syphilis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Staphylococcus aureus endocarditis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Rash predominantly on extremities",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Allergic purpura",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Brucellosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Disseminated gonococcal infection",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ecthyma gangrenosum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Erythema nodosum",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sporotrichosis (fever rare)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Pulmonary infiltrate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Atypical measles",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Coccidioidomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cryptococcosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fat embolism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Histoplasmosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mycoplasma pneumoniae",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            North American blastomycosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psittacosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rocky Mountain spotted fever",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sarcoidosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Varicella zoster",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from Sanders, CV. Diagnosis of the patient with fever and rash. In: The Skin and Infection: A Color Atlas and Text, Sanders, CV, Nesbitt, LT (Eds), Williams &amp; Wilkins, Baltimore, 1995. With permission from Hurst, JW (Ed). Medicine for the Practicing Physician., 3rd ed, Butterworth-Heinemann, Boston, 1992, pp. 273- 274.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23549=[""].join("\n");
var outline_f22_63_23549=null;
var title_f22_63_23550="Etiology of red urine";
var content_f22_63_23550=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Approach to the patient with red or brown urine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 371px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23550=[""].join("\n");
var outline_f22_63_23550=null;
var title_f22_63_23551="Elastosis perforans serpiginosa - arm";
var content_f22_63_23551=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F53188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F53188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Elastosis perforans serpiginosa",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyperkeratotic papules in a serpiginous distribution are present on the arm of this patient with elastosis perforans serpiginosa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_63_23551=[""].join("\n");
var outline_f22_63_23551=null;
